

# GLOBAL JOURNAL

OF MEDICAL RESEARCH: B

Pharma, Drug Discovery,  
Toxicology & Medicine



Prevalence of Health Related

Relation of Serum High-Sensitive

Highlights

Copper (II) Oxide Nanoparticles

Endocrine Disruptors in Endometriosis

Discovering Thoughts, Inventing Future



GLOBAL JOURNAL OF MEDICAL RESEARCH: B  
PHARMA, DRUG DISCOVERY, TOXICOLOGY & MEDICINE

---



GLOBAL JOURNAL OF MEDICAL RESEARCH: B  
PHARMA, DRUG DISCOVERY, TOXICOLOGY & MEDICINE

---

VOLUME 16 ISSUE 3 (VER. 1.0)

OPEN ASSOCIATION OF RESEARCH SOCIETY

© Global Journal of Medical Research. 2016.

All rights reserved.

This is a special issue published in version 1.0 of "Global Journal of Medical Research." By Global Journals Inc.

All articles are open access articles distributed under "Global Journal of Medical Research"

Reading License, which permits restricted use. Entire contents are copyright by of "Global Journal of Medical Research" unless otherwise noted on specific articles.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission.

The opinions and statements made in this book are those of the authors concerned. Ultraculture has not verified and neither confirms nor denies any of the foregoing and no warranty or fitness is implied.

Engage with the contents herein at your own risk.

The use of this journal, and the terms and conditions for our providing information, is governed by our Disclaimer, Terms and Conditions and Privacy Policy given on our website <http://globaljournals.us/terms-and-condition/menu-id-1463/>

By referring / using / reading / any type of association / referencing this journal, this signifies and you acknowledge that you have read them and that you accept and will be bound by the terms thereof.

All information, journals, this journal, activities undertaken, materials, services and our website, terms and conditions, privacy policy, and this journal is subject to change anytime without any prior notice.

Incorporation No.: 0423089  
License No.: 42125/022010/1186  
Registration No.: 430374  
Import-Export Code: 1109007027  
Employer Identification Number (EIN):  
USA Tax ID: 98-0673427

## Global Journals Inc.

(A Delaware USA Incorporation with "Good Standing"; Reg. Number: 0423089)

Sponsors: *Open Association of Research Society*  
*Open Scientific Standards*

### *Publisher's Headquarters office*

Global Journals® Headquarters  
945th Concord Streets,  
Framingham Massachusetts Pin: 01701,  
United States of America  
USA Toll Free: +001-888-839-7392  
USA Toll Free Fax: +001-888-839-7392

### *Offset Typesetting*

Global Journals Incorporated  
2nd, Lansdowne, Lansdowne Rd., Croydon-Surrey,  
Pin: CR9 2ER, United Kingdom

### *Packaging & Continental Dispatching*

Global Journals  
E-3130 Sudama Nagar, Near Gopur Square,  
Indore, M.P., Pin: 452009, India

### *Find a correspondence nodal officer near you*

To find nodal officer of your country, please  
email us at [local@globaljournals.org](mailto:local@globaljournals.org)

### *eContacts*

Press Inquiries: [press@globaljournals.org](mailto:press@globaljournals.org)  
Investor Inquiries: [investors@globaljournals.org](mailto:investors@globaljournals.org)  
Technical Support: [technology@globaljournals.org](mailto:technology@globaljournals.org)  
Media & Releases: [media@globaljournals.org](mailto:media@globaljournals.org)

### *Pricing (Including by Air Parcel Charges):*

#### *For Authors:*

22 USD (B/W) & 50 USD (Color)  
Yearly Subscription (Personal & Institutional):  
200 USD (B/W) & 250 USD (Color)

# GLOBAL JOURNALS CONSTITUTIONAL EDITORIAL BOARD

~INTEGRATED~

## *Shaoping Xiao*

BS, MS, Ph.D Mechanical Engineering,  
Northwestern University  
The University of Iowa  
Department of Mechanical and Industrial Engineering  
Center for Computer-Aided Design

## *Dr. A. Heidari*

Ph.D, D.Sc, Faculty of Chemistry  
California South University (CSU),  
United States

## *Maria Gullo*

Ph.D, Food Science and Technology  
University of Catania  
Department of Agricultural and Food Sciences  
University of Modena and Reggio Emilia, Italy

## *Bingyun Li*

Ph.D Fellow, IAES  
Guest Researcher, NIOSH, CDC, Morgantown, WV  
Institute of Nano and Biotechnologies  
West Virginia University, US

## *Lucian Baia*

Ph.D Julius-Maximilians University Würzburg, Germany  
Associate professor  
Department of Condensed Matter Physics and  
Advanced Technologies, Babes-Bolyai University,  
Romania

## *Houfa Shen*

Ph.D Manufacturing Engineering,  
Mechanical Engineering, Structural Engineering  
Department of Mechanical Engineering  
Tsinghua University, China

## *Dr. Osman Balci, Professor*

Department of Computer Science  
Virginia Tech, Virginia University  
Ph.D. and M.S. Syracuse University, Syracuse, New York  
M.S. and B.S. Bogazici University, Istanbul, Turkey  
Web: [manta.cs.vt.edu/balci](http://manta.cs.vt.edu/balci)

## *Dr. Miklas Scholz*

B.Eng. (equiv), PgC, MSc, Ph.D, CWEM, C.Env., CSci,  
C.Eng.  
Nigeria Health, Wellness and Fitness  
University of Lund

## *Qiang Wu*

Ph.D University of Technology, Sydney  
Department of Mathematics,  
Physics and Electrical Engineering  
Northumbria University

## *Dr. Audeh Ahmad Ahmad*

Amman Arab University For Higher Education  
Ph.D, Accounting-Ais  
Faculty of Business Administration  
Alalbyt University, Jordan, Amman

## *Sahraoui Chaieb*

PhD Physics and Chemical Physics  
M.S. Theoretical Physics  
B.S. Physics, École Normale Supérieure, Paris  
Associate Professor, Bioscience  
King Abdullah University of Science and Technology

## *Arshak Poghossian*

Ph.D Solid-State Physics  
Leningrad Electrotechnic Institute, Russia  
Institute of Nano and Biotechnologies  
Aachen University of Applied Sciences, Germany

*A. Stegou-Sagia*

Ph.D Mechanical Engineering, Environmental  
Engineering School of Mechanical Engineering  
National Technical University of Athens

*Giuseppe A Provenzano*

Irrigation and Water Management, Soil Science,  
Water Science Hydraulic Engineering  
Dept. of Agricultural and Forest Sciences  
Universita di Palermo, Italy

*Ciprian LĂPUȘAN*

Ph. D in Mechanical Engineering  
Technical University of Cluj-Napoca  
Cluj-Napoca (Romania)

*Hajjian Shi*

Ph.D Civil Engineering Structural Engineering  
Oakland, CA, United States

*Yogita Bajpai*

Ph.D Senior Aerospace/Mechanical/  
Aeronautical Engineering professional  
M.Sc. Mechanical Engineering  
M.Sc. Aeronautical Engineering  
B.Sc. Vehicle Engineering  
Orange County, California, USA

*Dr. Abdurrahman Arslanyilmaz*

Computer Science & Information Systems Department  
Youngstown State University  
Ph.D., Texas A&M University  
University of Missouri, Columbia  
Gazi University, Turkey  
Web:[cis.yzu.edu/~aarslanyilmaz/professional\\_web](http://cis.yzu.edu/~aarslanyilmaz/professional_web)

*Chao Wang*

Ph.D. in Computational Mechanics  
Rosharon, TX, USA

*Adel Al Jumaily*

Ph.D Electrical Engineering (AI)  
Faculty of Engineering and IT  
University of Technology, Sydney

*Kitipong Jaojaruek*

B. Eng, M. Eng D. Eng (Energy Technology, Asian  
Institute of Technology).  
Kasetsart University Kamphaeng Saen (KPS) Campus  
Energy Research Laboratory of Mechanical Engineering

*Mauro Lenzi*

Ph.D, Biological Science, Pisa University, Italy  
Lagoon Ecology and Aquaculture Laboratory  
Orbetello Pesca Lagunare Company

*Dr. Omid Gohardani*

M.Sc. (Computer Science), FICCT, U.S.A.  
Email: [yogita@computerresearch.org](mailto:yogita@computerresearch.org)

*Yap Yee Jiun*

B.Sc.(Manchester), Ph.D.(Brunel), M.Inst.P.(UK)  
Institute of Mathematical Sciences,  
University of Malaya,  
Kuala Lumpur, Malaysia

*Dr. Thomas Wischgoll*

Computer Science and Engineering,  
Wright State University, Dayton, Ohio  
B.S., M.S., Ph.D.  
(University of Kaiserslautern)  
Web:[avida.cs.wright.edu/personal/wischgol/index\\_eng.html](http://avida.cs.wright.edu/personal/wischgol/index_eng.html)

*Baziotis Ioannis*

Ph.D. in Petrology-Geochemistry-Mineralogy  
Lipson, Athens, Greece

*Dr. Xiaohong He*

Professor of International Business  
University of Quinnipiac  
BS, Jilin Institute of Technology; MA, MS, Ph.D,  
(University of Texas-Dallas)  
Web: [quinnipiac.edu/x1606.xml](http://quinnipiac.edu/x1606.xml)

*Burcin Becerik-Gerber*

University of Southern Californi  
Ph.D in Civil Engineering  
DDes from Harvard University  
M.S. from University of California, Berkeley  
M.S. from Istanbul Technical University  
Web: [i-lab.usc.edu](http://i-lab.usc.edu)

*Dr. Söhnke M. Bartram*

Department of Accounting and Finance  
Lancaster University Management School  
Ph.D. (WHU Koblenz)  
MBA/BBA (University of Saarbrücken)  
Web: [lancs.ac.uk/staff/bartras1/](http://lancs.ac.uk/staff/bartras1/)

*Dr. Söhnke M. Bartram*

Ph.D, (IT) in Faculty of Engg. & Tech.  
Professor & Head,  
Dept. of ISE at NMAM Institute of Technology

*Dr. Balasubramani R*

Department of Accounting and Finance  
Lancaster University Management School  
Ph.D. (WHU Koblenz)  
MBA/BBA (University of Saarbrücken)  
Web: [lancs.ac.uk/staff/bartras1/](http://lancs.ac.uk/staff/bartras1/)

*M. Meguellati*

Department of Electronics,  
University of Batna, Batna 05000, Algeria

*Dr. T. David A. Forbes*

Associate Professor and Range Nutritionist  
Ph.D Edinburgh University - Animal Nutrition  
M.S. Aberdeen University - Animal Nutrition  
B.A. University of Dublin- Zoology.  
Web: [essm.tamu.edu/people-info/faculty/forbes-david](http://essm.tamu.edu/people-info/faculty/forbes-david)

*Dr. Bassey Benjamin Esu*

B.Sc. Marketing; MBA Marketing; Ph.D Marketing  
Lecturer, Department of Marketing, University of Calabar  
Tourism Consultant, Cross River State Tourism  
Development Department  
Co-rdinator , Sustainable Tourism Initiative, Calabar,  
Nigeria

*Dr. Maciej Gućma*

Asistant Professor,  
Maritime University of Szczecin Szczecin, Poland  
Ph.D. Eng. Master Mariner  
Web: [www.mendeley.com/profiles/maciej-gucma/](http://www.mendeley.com/profiles/maciej-gucma/)

*Dr. Maciej Gućma*

Asistant Professor ,  
Maritime Univeristy of Szczecin Szczecin, Poland  
PhD. Eng. Master Mariner  
Web: [www.mendeley.com/profiles/maciej-gucma/](http://www.mendeley.com/profiles/maciej-gucma/)

*Dr. Fotini Labropulu*

Mathematics - Luther College, University of Regina  
Ph.D, M.Sc. in Mathematics  
B.A. (Honours) in Mathematics, University of Windsor  
Web: [luthercollege.edu/Default.aspx](http://luthercollege.edu/Default.aspx)

*Vesna Stanković Pejnović*

Ph. D. Philosopohy , Zagreb, Croatia  
Rusveltova, Skopje, Macedonia

*Dr. Miguel Angel Ariño*

Professor of Decision Sciences  
IESE Business School  
Barcelona, Spain (Universidad de Navarra)  
CEIBS (China Europe International Business School).  
Beijing, Shanghai and Shenzhen  
Ph.D. in Mathematics, University of Barcelona  
BA in Mathematics (Licenciatura)  
University of Barcelona  
Web: [web.iese.edu/MAArino/overview.axd](http://web.iese.edu/MAArino/overview.axd)

*Philip G. Moscoso*

Technology and Operations Management  
IESE Business School, University of Navarra  
Ph.D in Industrial Engineering and Management,  
ETH Zurich , M.Sc. in Chemical Engineering,  
ETH Zurich Link: Philip G. Moscoso personal webpage

*Dr. Mihaly Mezei*

Associate Professor  
Department of Structural and Chemical Biology  
Mount Sinai School of Medical Center  
Ph.D., Etsv Lornd University, Postdoctoral Training,  
New York University, MSSM home:  
<https://www.mountsinai.org/Find%20A%20Faculty/profile.do?id=0000072500001497192632>  
Lab home - software,  
publications: <https://inka.mssm.edu/~mezei>  
Department: <https://atlas.physbio.mssm.edu>

*Vivek Dubey (HON.)*

MS (Industrial Engineering),  
MS (Mechanical Engineering)  
University of Wisconsin  
FICCT  
Editor-in-Chief, USA  
[editorusa@globaljournals.org](mailto:editorusa@globaljournals.org)

*Dr. Carlos García Pont*

Associate Professor of Marketing  
IESE Business School, University of Navarra  
Doctor of Philosophy (Management),  
Massachusetts Institute of Technology (MIT)  
Master in Business Administration, IESE,  
University of Navarra  
Degree in Industrial Engineering,  
Universitat Politècnica de Catalunya  
Web: [iese.edu/aplicaciones/faculty/facultyDetail.asp](http://iese.edu/aplicaciones/faculty/facultyDetail.asp)

*Dr. Sanjay Dixit, M.D.*

Director, EP Laboratories, Philadelphia VA Medical Center  
Cardiovascular Medicine - Cardiac Arrhythmia  
University of Penn School of Medicine  
Web: [pennmedicine.org/wagform/MainPage.aspx?](http://pennmedicine.org/wagform/MainPage.aspx?)

*Dr. Pina C. Sanelli*

Associate Professor of Radiology  
Associate Professor of Public Health  
Weill Cornell Medical College  
Associate Attending Radiologist  
NewYork-Presbyterian Hospital  
MRI, MRA, CT, and CTA  
Neuroradiology and Diagnostic Radiology  
M.D., State University of New York at Buffalo,  
School of Medicine and Biomedical Sciences  
Web: [weillcornell.org/pinasanelli/](http://weillcornell.org/pinasanelli/)

*Er. Suyog Dixit*

(M.Tech), BE (HONS. in CSE), FICCT  
SAP Certified Consultant  
CEO at IOSRD, GAOR OSS  
Technical Dean, Global Journals Inc.(US)  
Website: [www.suyogdixit.com](http://www.suyogdixit.com)  
Email: [suyog@suyogdixit.com](mailto:suyog@suyogdixit.com),  
[deanind@globaljournals.org](mailto:deanind@globaljournals.org)



*Er. Pritesh Rajvaidya*

Computer Science Department  
California State University  
BE (Computer Science), FICCT  
Technical Dean, USA  
Email: [pritesh@computerresearch.org](mailto:pritesh@computerresearch.org),  
[deanusa@globaljournals.org](mailto:deanusa@globaljournals.org)

*Dr Apostolos Ch. Zarros*

DM, Degree (Ptychio) holder in Medicine,  
National and Kapodistrian University of Athens  
MRes, Master of Research in Molecular Functions in  
Disease,  
University of Glasgow  
FRNS, Fellow, Royal Numismatic Society  
Member, European Society for Neurochemistry  
Member, Royal Institute of Philosophy  
Scotland, United Kingdom

*Dr. Han-Xiang Deng*

MD., Ph.D  
Associate Professor and Research Department  
Division of Neuromuscular Medicine  
Davee Department of Neurology and Clinical  
Neurosciences  
Northwestern University Feinberg School of Medicine  
Web: [neurology.northwestern.edu/faculty/deng.html](http://neurology.northwestern.edu/faculty/deng.html)

*Dr. Roberto Sanchez*

Associate Professor  
Department of Structural and Chemical Biology  
Mount Sinai School of Medicine  
Ph.D., The Rockefeller University  
Web: [mountsinai.org/](http://mountsinai.org/)

*Jixin Zhong*

Department of Medicine,  
Affiliated Hospital of Guangdong Medical College,  
Zhanjiang, China Davis Heart and Lung Research Institute,  
The Ohio State University, Columbus, OH 43210, USA

*Dr. Wen-Yih Sun*

Professor of Earth and Atmospheric Sciences  
Purdue University, Director  
National Center for Typhoon and Flooding Research,  
Taiwan  
University Chair Professor  
Department of Atmospheric Sciences,  
National Central University, Chung-Li, Taiwan  
University Chair Professor  
Institute of Environmental Engineering,  
National Chiao Tung University, Hsin-chu, Taiwan.  
Ph.D., MS The University of Chicago, Geophysical Sciences  
BS National Taiwan University, Atmospheric Sciences  
Web: [event.nchc.org.tw/2009](http://event.nchc.org.tw/2009)

*Dr. Michael R. Rudnick*

M.D., FACP  
Associate Professor of Medicine  
Chief, Renal Electrolyte and Hypertension Division (PMC)  
Penn Medicine, University of Pennsylvania  
Presbyterian Medical Center, Philadelphia  
Nephrology and Internal Medicine  
Certified by the American Board of Internal Medicine  
Web: [uups.upenn.edu/](http://uups.upenn.edu/)

*Dr. Aziz M. Barbar, Ph.D.*

IEEE Senior Member  
Chairperson, Department of Computer Science  
AUST - American University of Science & Technology  
Alfred Naccash Avenue - Ashrafieh

*Dr. Minghua He*

Department of Civil Engineering  
Tsinghua University  
Beijing, 100084, China

*Anis Bey*

Dept. of Comput. Sci.,  
Badji Mokhtar-Annaba Univ.,  
Annaba, Algeria

*Chutisant Kerdvibulvech*

Dept. of Inf.& Commun. Technol.,  
Rangsit University, Pathum Thani, Thailand  
Chulalongkorn University, Thailand  
Keio University, Tokyo, Japan

*Dr. Wael Abdullah*

Elhelece Lecturer of Chemistry,  
Faculty of science, Gazan Univeristy,  
KSA. Ph. D. in Inorganic Chemistry,  
Faculty of Science, Tanta University, Egypt

*Yaping Ren*

School of Statistics and Mathematics  
Yunnan University of Finance and Economics  
Kunming 650221, China

*Ye Tian*

The Pennsylvania State University  
121 Electrical Engineering East  
University Park, PA 16802, USA

*Diego González-Aguilera*

Ph.D. Dep. Cartographic and Land Engineering,  
University of Salamanca, Ávila, Spain

*Maciej Gućma*

PhD. Eng. Master Mariner  
Warsaw University of Technology  
Maritime University of Szczecin  
Waly Chrobrego 1/2 70-500 Szczecin, Poland

*Tao Yang*

Ph.D, Ohio State University  
M.S. Kansas State University  
B.E. Zhejiang University

*Dr. Feng Feng*

Boston University  
Microbiology, 72 East Concord Street R702  
Duke University  
United States of America

*Shengbing Deng*

Departamento de Ingeniería Matemática,  
Universidad de Chile.  
Facultad de Ciencias Físicas y Matemáticas.  
Blanco Encalada 2120, piso 4.  
Casilla 170-3. Correo 3. - Santiago, Chile

*Claudio Cuevas*

Department of Mathematics  
Universidade Federal de Pernambuco  
Recife PE Brazil

*Alis Puteh*

Ph.D. (Edu.Policy) UUM  
Sintok, Kedah, Malaysia  
M.Ed (Curr. & Inst.), University of Houston, USA

*Dr. R.K. Dixit(HON.)*

M.Sc., Ph.D., FICCT Chief Author, India  
Email: authorind@globaljournals.org

*Dodi Irawanto*

PhD, M.Com, B.Econ Hons.  
Department of Management,  
Faculty of Economics and Business, Brawijaya University  
Malang, Indonesia

*Ivona Vrdoljak Raguz*

University of Dubrovnik, Head,  
Department of Economics and Business Economics,  
Croatia

*Prof Adrian Armstrong*

BSc Geography, LSE, 1970  
PhD Geography (Geomorphology)  
Kings College London 1980  
Ordained Priest, Church of England 1988  
Taunton, Somerset, United Kingdom

*Thierry FEUILLET*

Géolittomer – LETG UMR 6554 CNRS  
(Université de Nantes)  
Institut de Géographie et d'Aménagement  
Régional de l'Université de Nantes.  
Chemin de la Censive du Tertre – BP, Rodez

*Yongbing Jiao*

Ph.D. of Marketing  
School of Economics & Management  
Ningbo University of Technology  
Zhejiang Province, P. R. China

*Cosimo Magazzino*

Roma Tre University  
Rome, 00145, Italy

*Christos Kalialakis*

Ph.D., Electrical and Electronic Engineering,  
University of Birmingham,  
UKM.Sc., Telecommunications, Greece B.Sc, Physics,  
Aristotle University of Thessaloniki, Greece

*Alex W. Dawotola.*

Hydraulic Engineering Section,  
Delft University of Technology,  
Stevinweg, Delft, Netherlands

*Luisa dall'Acqua*

PhD in Sociology (Decisional Risk sector),  
Master MU2, College Teacher in Philosophy (Italy),  
Edu-Research Group, Zürich/Lugano

*Xianghong Qi*

University of Tennessee  
Oak Ridge National Laboratory  
Center for Molecular Biophysics  
Oak Ridge National Laboratory  
Knoxville, TN 37922, United States

*Gerard G. Dumancas*

Postdoctoral Research Fellow,  
Arthritis and Clinical Immunology Research Program,  
Oklahoma Medical Research Foundation  
Oklahoma City, OK  
United States

*Vladimir Burtman*

Research Scientist  
The University of Utah, Geophysics  
Frederick Albert Sutton Building, 115 S 1460 E Room 383  
Salt Lake City, UT 84112, USA

*Jalal Kafashan*

Mechanical Engineering, Division of Mechatronics  
KU Leuven, BELGIUM

*Zhibin Lin*

Center for Infrastructure Engineering Studies  
Missouri University of Science and Technology  
ERL, 500 W. 16th St. Rolla,  
Missouri 65409, USA

*Lzzet Yavuz*

MSc, PhD, D Ped Dent.  
Associate Professor,  
Pediatric Dentistry Faculty of Dentistry,  
University of Dicle, Diyarbakir, Turkey

*Prof. Dr. Eman M. Gouda*

Biochemistry Department,  
Faculty of Veterinary Medicine, Cairo University,  
Giza, Egypt

*Della Ata*

BS in Biological Sciences  
MA in Regional Economics  
Hospital Pharmacy  
Pharmacy Technician Educator

*Muhammad Hassan Raza, PhD*

Engineering Mathematics  
Internetworking Engineering, Dalhousie University,  
Canada

*Charles A. Rarick*

Ph.D.  
Professor of International Business  
College of Business  
Purdue University Northwest  
Hammond, Indiana USA

*Asunción López-Varela*

BA, MA (Hons), Ph.D (Hons)  
Facultad de Filología.  
Universidad Complutense Madrid  
29040 Madrid, Spain

*Bondage Devanand Dhondiram*

Ph.D  
No. 8, Alley 2, Lane 9, Hongdao station,  
Xizhi district, New Taipei city 221, Taiwan (ROC)

*Latifa Oubedda*

National School of Applied Sciences,  
University Ibn Zohr, Agadir, Morocco  
Lotissement Elkhier N°66  
Bettana Salé Maroc

*Dr. Hai-Linh Tran*

PhD in Biological Engineering  
Department of Biological Engineering  
College of Engineering Inha University, Incheon, Korea

*Shun-Chung Lee*

Department of Resources Engineering,  
National Cheng Kung University, Taiwan

## CONTENTS OF THE ISSUE

---

- i. Copyright Notice
- ii. Editorial Board Members
- iii. Chief Author and Dean
- iv. Contents of the Issue
  1. Assessment of Volume Status of Hemodialysis Patients using Sonographic Lung Comets. *1-6*
  2. Copper (II) Oxide Nanoparticles Induce High Toxicity in Human Neuronal Cell. *7-14*
  3. The Relation of Serum High-Sensitive C- Reactive Protein to Serum Lipid Profile, Vitamin D and Other Variables in a Group of Hypertensive Patients in Erbil-Iraq. *5-20*
  4. Endocrine Disruptors in Endometriosis. *21-24*
  5. Prevalence of Health Related Disability among Community Dwelling Urban Elderly from Middle Socio-Economic Strata in Serampore. *25-31*
- v. Fellows
- vi. Auxiliary Memberships
- vii. Process of Submission of Research Paper
- viii. Preferred Author Guidelines
- ix. Index



GLOBAL JOURNAL OF MEDICAL RESEARCH: B  
PHARMA, DRUG DISCOVERY, TOXICOLOGY & MEDICINE  
Volume 16 Issue 3 Version 1.0 Year 2016  
Type: Double Blind Peer Reviewed International Research Journal  
Publisher: Global Journals Inc. (USA)  
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Assessment of Volume Status of Hemodialysis Patients using Sonographic Lung Comets

By Hala S El-Wakil, Iman E El-Gohary, Doaa M. Emara & Reham Abd El Wahab

*Alexandria University*

**Abstract- Background:** Fluid balance is important in patients with renal impairment and undergoing hemodialysis. “Dry” weight is usually assessed clinically, and also, bioimpedance is considered reliable. The use of chest ultrasound to detect lung water received growing attention in clinical research in intensive care patients and in patients with heart failure. Recently ultrasonographic lung comets (counting B-lines artifact) evaluates extravascular lung water while ultrasonography of inferior vena cava (IVC) estimates central venous pressure, so ultrasound is considered as a useful tool to evaluate the hydration status of hemodialysis patients.

**Objectives:** The study was designed to use lung ultrasound to assess lung congestion before and after a dialysis session in correlation to clinical signs and symptoms and the achieved dry weight in end stage renal disease patients on maintenance hemodialysis.

**Keywords:** *hypervolemia, hemodialysis, dry weight, ultrafiltration, lung comets score.*

**GJMR-B Classification :** *NLMC Code: QV 4*



*Strictly as per the compliance and regulations of:*



© 2016. Hala S El-Wakil, Iman E El-Gohary, Doaa M. Emara & Reham Abd El Wahab. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License <http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

# Assessment of Volume Status of Hemodialysis Patients using Sonographic Lung Comets

Hala S El-Wakil <sup>α</sup>, Iman E El-Gohary <sup>σ</sup>, Doaa M. Emara <sup>ρ</sup> & Reham Abd El Wahab <sup>ω</sup>

**Abstract- Background:** Fluid balance is important in patients with renal impairment and undergoing hemodialysis. "Dry" weight is usually assessed clinically, and also, bioimpedance is considered reliable. The use of chest ultrasound to detect lung water received growing attention in clinical research in intensive care patients and in patients with heart failure. Recently ultrasonographic lung comets (counting B-lines artifact) evaluates extravascular lung water while ultrasonography of inferior vena cava (IVC) estimates central venous pressure, so ultrasound is considered as a useful tool to evaluate the hydration status of hemodialysis patients.

**Objectives:** The study was designed to use lung ultrasound to assess lung congestion before and after a dialysis session in correlation to clinical signs and symptoms and the achieved dry weight in end stage renal disease patients on maintenance hemodialysis.

**Methods:** The present study included 25 patients on maintenance hemodialysis in Alexandria University Hospitals. All the patients were subjected to thorough history taking with special concern on grade of dyspnea and ultrafiltration volume, as well as full clinical examination before and after dialysis including vital signs and signs of hypervolemia as congested neck veins, fine basal crepitations, congested liver and lower limb edema. Radiological examination including ultrasound lung comets score and diameter of hepatic portion of inferior vena cava (IVC) before and after dialysis session.

**Results:** The mean lung comets score before dialysis was high and decreased significantly after dialysis. There was a significant positive correlation between ultrafiltration volume and the absolute change of lung comets score while there was no correlation between the ultrafiltration volume and the absolute change of IVC diameter. There was a significant correlation between lung comets score and grade of dyspnea before dialysis as well as after dialysis. There was a significant positive correlation between the grade of lung comets and IVC diameter both before and after dialysis.

**Conclusions:** Ultrasound lung comets score is a promising sensitive tool for assessment of the degree of lung congestion and hence the dry weight achievement in end stage renal disease patients on maintenance hemodialysis.

**Keywords:** hypervolemia, hemodialysis, dry weight, ultrafiltration, lung comets score.

**Author α σ:** Department of Internal Medicine, Faculty of Medicine, Alexandria University, Egypt. e-mail: imanalgohary@yahoo.com

**Author ρ:** Department of Radiodiagnosis and Intervention, Faculty of Medicine, Alexandria University, Egypt.

**Author ω:** Department of Emergency Medicine, Faculty of Medicine, Alexandria University, Egypt.

## I. INTRODUCTION

In patients with end-stage renal disease (ESRD) on intermittent hemodialysis (HD), it is vital to maintain fluid status within an optimal range to avoid circulatory complications. Clinical assessment of body weight change, Neck veins congestion, edema together with blood pressure and chest x-ray are usually used for evaluation of fluid status.<sup>(1)</sup> However, clinical evaluation alone is not accurate enough for evaluation of HD patients, so other methods such as biochemical markers, bio-impedance analysis and inferior vena cava diameter have been developed to assess the fluid status, yet no single method is considered a gold standard and combination of more than one method should be used for more accurate assessment.<sup>(1,2)</sup>

The main issue for the achievement of dry weight in HD patients is that ultrafiltration should be tailored to the individual patient's hemodynamic tolerance taking into account cardiac performance, which is very often compromised in ESRD patients.<sup>(3)</sup>

Lung ultrasound is simple, non-invasive, non-ionizing, available, and inexpensive which is suitable for the assessment of ideal body weight in maintenance hemodialysis (MHD) patients.<sup>(4-7)</sup> Moreover, lung comets can be used in association with IVC diameter for more accurate assessment of dry weight in HD patients.<sup>(8)</sup>

So, the aim of this work was to use the lung ultrasound to assess lung congestion before and after a dialysis session in correlation to clinical signs and symptoms and the achieved dry weight in end stage renal disease patients on maintenance hemodialysis.

## II. PATIENTS & METHODS

The present study included 25 patients on maintenance hemodialysis in Alexandria University Hospitals. Patients with congestive heart failure, those with any problem in the right side of the heart and patients with interstitial lung fibrosis, lung malignancy or mediastinal syndrome and obese patients were excluded from the study. An informed consent was taken from all patients and the study was conducted according to the declaration of Helsinki.

All the patients were subjected to thorough history taking with special concern on grade of dyspnea (it is assessed by The New York Heart Association (NYHA) classification) and ultrafiltration volume, as well as full clinical examination before and after dialysis

including vital signs (Blood pressure; supine and standing position, respiratory rate, pulse, and temperature were measured before and after the dialysis session) and signs of hypervolemia as congested neck veins, fine basal crepitations, congested liver and lower limb oedema. Routine laboratory investigations were done once before dialysis. Radiological examination including ultrasound lung comets score and diameter of hepatic portion of inferior vena cava (IVC) before and after dialysis session. We were using a commercially available ultrasonographic equipment (Siemens medical solution, with 5-10 MHz linear or 2-5 MHz convex probe). The time needed for the chest US ranged between 10 to 15 min. All patients were subjected to chest U/S examination for lung comets measurements before and within 6 hours after the dialysis session for the assessment of the lung congestion. Patients were in a supine position during the examination. Ultrasound examination of the anterolateral chest was carried out with longitudinal scan of the right and left hemithoraces, **from the second to the fourth** (on the right side to the fifth) intercostal space. In each intercostal space, the number of B-lines was counted at the parasternal, midclavicular, anterior axillary, and midaxillary lines for a total of 28 sectors examined. The total number of B-lines was the sum of the artefacts recorded in the 28 sectors explored yielding a score called **lung comet score**. The collected data were recorded in a table and the lung comets scores for each patient before and after dialysis, the absolute change of lung comets score and the percentage change of the lung comets score were calculated.<sup>(7)</sup>

### III. RESULTS

The patients were classified into three groups according to their lung comets grades (mild, moderate, severe) before and after dialysis:

#### a) *Lung comets grades before dialysis*

The patients were classified as follow: only one patient had mild lung comets grade (4%), two patients had moderate lung comets grade (8%), 22 patients had severe lung comets grade (88%), Table (I)

#### b) *Lung comets grades after dialysis*

The patients were classified as follow: 6 patients had mild lung comets grade (24%), 9 patients had moderate lung comets grade (36%), 10 patients had severe lung comets grade (40%), Table (I).

The patients were classified before dialysis into groups according to presence of dyspnea (NYHA class II, III,VI) or absence of dyspnea (NYHA class I) and the grade of lung comets (mild, moderate, severe):

25 patients had dyspnea (NYHA class II, III, VI) (100%) before dialysis and they were classified as follow: one patients had mild lung comets grade and the remaining 24 patients had either moderate or severe lung comets grade, Table (II).

The patients were classified after dialysis into groups according to presence of dyspnea (NYHA class II, III,VI) or absence of dyspnea (NYHA class I) and the grade of lung comets (mild, moderate, severe):

Out of the 25 patients there were 6 patients that had no dyspnea (NYHA class I) after dialysis and they were classified as follow: 5 patients had mild lung comets grade (20%) and one patient had moderate lung comets grade (4%) while 19 patients had dyspnea (NYHA class II, III,VI) and they were classified as follow: 18 patients had either moderate or severe lung comets grade (72%) while only one patient had mild lung comets grade (4%). **Table (II).**

There was a significant correlation between lung comets score before dialysis and NYHA class of dyspnea before dialysis, Table (III).

There was a highly significant correlation between lung comets score after dialysis and NYHA class of dyspnea after dialysis, Table (III).

Table (IV) shows the correlation between lung comets score and grade before and after dialysis, their percent and absolute change and clinical data (blood pressure, pulse and respiratory rate).

There was a significant correlation between ultrafiltration volume and the lung comets score absolute change while there was no correlation between the ultrafiltration volume and the IVCD absolute change or IVCD percentage change or the lung comets percentage change Table (V).

Table (VI) shows the correlation between lung comets and IVC diameter before and after dialysis.

### IV. DISCUSSION

The mean age of the studied group was 47.39 years that is comparable with other studies in the developing countries in which the age of hemodialysis patients' age ranged between 32 – 42 years while the age of our patients were much lower than that in the developed world in which the hemodialysis patients' age ranged between 52 to 63 years.<sup>(9-11)</sup> Among the reasons for this difference are the delay in detecting renal disease and the failure to institute controlling and preventive measures in patients with progressive renal failure, both of which result in faster deterioration of renal function and progression to ESRD. Late referrals lead to a faster progression of co-morbid conditions, increase the cost of therapy, and worsen overall patient survival as mentioned in a study conducted by Kher<sup>(10)</sup> that studied the end stage renal disease in the developing countries.

In our study, patients with interstitial lung fibrosis were excluded because the thickened interlobular septae characterizing fibrosis may not be modified by the state of hydration or congestion.<sup>(7)</sup> We also excluded the presence of lung malignancy and mediastinal lesions to avoid their effect in development of dyspnea or orthopnea in the studied patients and to



avoid the pulmonary congestion resulted from pulmonary veins compression that may be encountered in case of mediastinal lesions.<sup>(12,13)</sup> We also excluded obesity as large body habitus also degrades image quality, making it difficult or impossible to obtain adequate images for clinical interpretation.<sup>(14)</sup>

In our patients three main underlying cause of chronic kidney disease were found to be the hypertension (28%) followed by chronic glomerulonephritis (20%) and diabetes (16%) and this quietly matches the result of a study conducted by Barsoum et al, about burden of chronic kidney disease in North Africa that showed hypertension, glomerulonephritis and diabetes as the major underlying cause of chronic kidney disease.<sup>(15)</sup>

In the present study hypertension was found in 80 % of our patients, which means that most of our cases suffer from high risk of developing cardiovascular complications.<sup>(16-18)</sup> Our result is relatively comparable with results found in several studies like that conducted by Portolés et al,<sup>(19)</sup>

In our study there was a significant reduction in both of systolic supine blood pressure, Diastolic supine blood pressure, the systolic standing blood pressure and the diastolic standing blood pressure after dialysis in comparison to predialysis values. The mean blood pressure before dialysis for the whole group ranged between 80-133.33 mmHg with a mean of  $111.33 \pm 15.25$  mmHg while the mean blood pressure after dialysis for the whole group ranged between 70-116.67mmHg with a mean of  $90.93 \pm 14.58$  mmHg with a significant change .The mean blood pressure significantly reduced towards normal range and this could be attributed to the underlying pathology of hypertension found among our cohort to be volume dependent. This matches a study conducted by Lazarus et al,<sup>(20)</sup> who confirmed that removing excess salt and water during maintenance hemodialysis normalizes BP in at least 70% of their cases and attributed to that extracellular volume expansion causes hypertension in approximately 75% of patients with chronic renal failure and therefore their cases were found to be responsive to hemodialysis.

In the present study 68% of the whole group were receiving calcium channel blockers as antihypertensive drugs which means that calcium channel blockers (CCBs) are widely used in this category of hypertensive patients on maintenance hemodialysis that matches a study conducted by Kestenbaum et al,<sup>(21)</sup> that showed that greater than half of the ESRD were receiving calcium channel blockers and a lower relative risk of mortality reported in patients taking a calcium channel blocker. The use of any calcium channel blockers was associated with a 21% lower risk of all cause mortality and a 26% lower risk of cardiovascular specific mortality.

The lung comets score before dialysis in our study ranged between 7-136 with a mean of  $54.72 \pm 28.47$  while the lung comets score after dialysis for whole patients ranged between 3-74 with a mean of  $28.52 \pm 19.88$  with a significant change ( $p=0.00$ ). That matches a study conducted by Noble et al.<sup>(22)</sup>

We also found a significant correlation between lung comets score before dialysis and NYHA class of dyspnea before dialysis and a highly significant correlation between lung comets score after dialysis and NYHA class of dyspnea after dialysis. This means that the lung comets score is a more sensitive tool in achieving dry weight rather than the clinical examination only and it reflects the state of the hypervolemia, especially in the extra vascular lung water (EVLW) compartment, that is considered an important factor related to the risk for the cardiac compromise.

Our results showed that 6 patients having pulmonary congestion, as evidenced by presence of mild lung comets in 5 patients out of them and moderate degree of lung comets in one patient of them after hemodialysis, however, they did not show any clinical manifestations and they had no dyspnea with their ordinary physical activity "NYHA class I" and this demonstrates the sensitivity of the lung comets as a marker for pulmonary congestion in asymptomatic patients, therefore the lung comets could be the only indicator for lung congestion in the preclinical phase in hemodialysis patients. This result matches a study conducted by Mallamaci et al.<sup>(5)</sup>

There was a significant positive correlation between lung comets grade and IVCD before and after dialysis and also between the lung comets score and the IVCD. This reflects the reliability of the lung comets score in assessment of the hydration state in relation to the other reliable tool like IVCD. It could be used as an easy tool for hydration state assessment in comparison to IVCD which is somewhat difficult maneuver needing professional skills. Our result matches a study conducted by Basso et al.<sup>(23)</sup>

In our study, there was a highly significant positive correlation between absolute change of lung comets after dialysis and body ultrafiltration volume during dialysis and this matches with the study done by Vitturi et al.<sup>(24)</sup>

In the present, we found that there was a significant reduction in IVCD after dialysis but there was no correlation between the ultrafiltration volume and the IVCD absolute change or IVCD percentage change, in contrast to the significant correlation found between the lung comets absolute score change and the ultrafiltration volume. This indicates the superiority of ULCs over IVCD as a marker to ultrafiltration volume.

## V. CONCLUSION

Ultrasound lung comets score is highly correlated with the clinical signs and symptoms and even may precede the development of symptoms in hemodialysis patients. Moreover, lung comets score is highly correlated with ultrafiltration volume, thus, it could be used as a good marker for achieving dry weight in dialysis patients. Furthermore, ultrasound lung comets score is more superior to IVCD in assessing the volume status in hemodialysis patients and hence the target dry weight for those patients.

## REFERENCES RÉFÉRENCES REFERENCIAS

1. Wu C-C, Lin Y-P, Yu W-C, Lee W-S, Hsu T-L, Ding PY-A, et al. The assessment of fluid status in hemodialysis patients: usefulness of the Doppler echocardiographic parameters. *Nephrol Dial Transplant* 2004; 19(3): 644–51.
2. Özkan G, Ulusoy Ş. Acute Complications of Hemodialysis. Turkey: Karadeniz Technical University, School of Medicine, Department of Nephrology; 2011.
3. Jaeger JQ, Mehta RL. Assessment of Dry Weight in Hemodialysis An Overview *J Am Soc Nephrol* 1999; 10(2):392–403.
4. Siriopol D, Hogas S, Voroneanu L, Onofriescu M, Apetrii M, Oleniuc M, et al. Predicting mortality in haemodialysis patients: a comparison between lung ultrasonography, bioimpedance data and echocardiography parameters. *Nephrol Dial Transplant* 2013; 28(11): 2851–9.
5. Mallamaci F, Benedetto FA, Tripepi R, Rastelli S, Castellino P, Tripepi G, et al. Detection of pulmonary congestion by chest ultrasound in dialysis patients. *JACC Cardiovasc Imaging* 2010; 3(6): 586–94.
6. Donadio C, Bozzoli L, Colombini E, Pisanu G, Ricchiuti G, Picano E, et al. Effective and timely evaluation of pulmonary congestion: qualitative comparison between lung ultrasound and thoracic bioelectrical impedance in maintenance hemodialysis patients. *Medicine (Baltimore)* 2015; 94(6): e473.
7. Trezzi M, Torzillo D, Ceriani E, Costantino G, Caruso S, Damavandi PT, et al. Lung ultrasonography for the assessment of rapid extravascular water variation: evidence from hemodialysis patients. *Intern Emerg Med* 2013; 8(5): 409–15.
8. Basso F, Milan Manani S, Cruz DN, Teixeira C, Brendolan A, Nalesso F, et al. Comparison and Reproducibility of Techniques for Fluid Status Assessment in Chronic Hemodialysis Patients. *Cardiorenal Med* 2013; 3(2): 104–12.
9. Arabi Z. Hemodialysis in an underserved area (Hama, Syria): A base for a situation analysis project. *Avicenna J Med* 2012; 2(2): 29–33.
10. Kher V. End-stage renal disease in developing countries. *Kidney Int* 2002; 62(1): 350–62.
11. Rutkowski B, Ritz E. Explosion of renal replacement therapy after the implosion of the Soviet Empire. *Ethn Dis* 2006; 16(2 Suppl 2): S2–17 – 9.
12. Ripamonti C. Management of dyspnea in advanced cancer patients. *Support Care Cancer* 1999; 7(4): 233–43.
13. Datt V, Tempe DK, others. Airway management in patients with mediastinal masses. *Indian J Anaesth* 2005; 49: 344–52.
14. McAdams HP, Samei E, Dobbins J, Tourassi GD, Ravin CE. Recent Advances in Chest Radiography. *Radiology* 2006; 241(3): 663–83.
15. Barsoum RS. Burden of chronic kidney disease: North Africa. *Kidney Int Suppl* 2013; 3(2): 164–6.
16. Cheigh JS, Milite C, Sullivan JF, Rubin AL, Stenzel KH. Hypertension is not adequately controlled in hemodialysis patients. *Am J Kidney Dis* 1992; 19(5): 453–9.
17. Fishbane S, Natke E, Maesaka JK. Role of volume overload in dialysis-refractory hypertension. *Am J Kidney Dis* 1996; 28(2): 257–61.
18. Ozkahya M. Pharmacological and non-pharmacological treatment of hypertension in dialysis patients. *Kidney Int Suppl* 2013; 3(4): 380–2.
19. Portolés J, López-Gómez JM, Aljama P. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)]. *Nefrologia* 2005; 25(3): 297–306.
20. Lazarus JM, Hampers CL, Merrill JP. Hypertension in chronic renal failure: treatment with hemodialysis and nephrectomy. *Arch Intern Med* 1974; 133(6): 1059–66.
21. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C. Calcium channel blocker use and mortality among patients with end-stage renal disease. *Kidney Int* 2002; 61(6): 2157–64.
22. Noble VE, Murray AF, Capp R, Sylvia-Reardon MH, Steele DJR, Liteplo A. Ultrasound assessment for extravascular lung water in patients undergoing hemodialysis. Time course for resolution. *Chest* 2009; 135(6): 1433–9.
23. Basso F, Milan Manani S, Cruz DN, Teixeira C, Brendolan A, Nalesso F, et al. Comparison and Reproducibility of Techniques for Fluid Status Assessment in Chronic Hemodialysis Patients. *Cardiorenal Med* 2013; 3(2): 104–12.
24. Vitturi N, Dugo M, Soattin M, Simoni F, Maresca L, Zagatti R, et al. Lung ultrasound during hemodialysis: the role in the assessment of volume status. *Int Urol Nephrol* 2013; 46(1): 169–74.

Table (I) : Demonstrates patients' lung comets grades before and after dialysis

Lung comets grade	Before dialysis		After dialysis	
	Frequency	Percent	Frequency	Percent
Mild	1	4	6	24
Moderate	2	8	9	36
Severe	22	88	10	40
Total	25	100	25	100

Table (II) : Classification of the patients before and after dialysis according to presence or absence of dyspnea and the grade of lung comets (mild, moderate, severe)

Parameter	Before dialysis				After dialysis			
	Without dyspnea "NYHA class I"		With dyspnea "NYHA class II,III,VI"		Without dyspnea "NYHA class I"		With dyspnea "NYHA class II,III,VI"	
	Frequency	Percent	Frequency	Percent	Frequency	Percent	Frequency	Percent
Mild lung comets degree	0	0	1	4	5	20	1	4
Moderate or severe lung comets degree	0	0	24	96	1	4	18	72
Total number	0	0	25	100	6	24	19	76

Table (III) : Correlation between dyspnea (assessed by NYHA classification) and lung comets score before and after dialysis

		Lung comets score before dialysis		Lung comets score after dialysis	
Dyspnea before dialysis	r	0.418*		0.463*	
	p	0.037		0.020	
Dyspnea after dialysis	r	0.496*		0.635**	
	p	0.012		0.001	

Pearson Correlation (r)

\*Correlation is significant  $\leq 0.05$  level (2-tailed).

\*\*Correlation is highly significant at  $\leq 0.01$  level (2-tailed).

Table (IV) : Correlation between ultrasound lung comets score and ultrasound lung comets grade before and after dialysis with clinical data

Parameters		ULCs score before dialysis	ULCs grade before dialysis	ULCs grade after dialysis	ULs score after dialysis	ULCs score percentage change	ULCs score Absolute Change
Mean supine BP before dialysis	r	0.222	0.281	0.358	0.286	0.406*	-0.049
	p	0.285	0.173	0.079	0.166	0.044	0.816
Mean Standing BP before dialysis	r	0.230	0.266	0.302	0.233	0.276	-0.144
	p	0.270	0.198	0.142	0.262	0.181	0.491
Mean supine BP after dialysis	r	0.266	0.305	0.427*	0.307	0.390	-0.111
	p	0.199	0.138	0.033	0.135	0.054	0.597
Mean standing BP after dialysis	r	0.319	0.356	0.363	0.286	0.204	0.257
	p	0.120	0.080	0.075	0.165	0.327	0.215
Pulse before dialysis	r	0.606**	0.192	0.639**	0.682**	0.543**	-0.281
	p	0.001	0.359	0.001	0.000	0.005	0.174
Pulse after dialysis	r	0.598**	0.225	0.719**	0.720**	0.698**	-0.206
	p	0.002	0.281	0.000	0.000	0.000	0.323
Pulse percentage change	r	-0.071	0.042	0.053	0.002	0.209	0.156

	p	0.737	0.841	0.800	0.992	0.317	0.457
RR before dialysis	r	0.485*	0.080	0.476*	0.482*	0.342	-0.321
	p	0.014	0.702	0.016	0.015	0.095	0.118
RR after dialysis	r	0.489*	0.004	0.561**	0.580**	0.554**	-0.180
	p	0.013	0.985	0.004	0.002	0.004	0.388
RR percentage change	r	0.039	-0.186	0.173	0.211	0.407*	0.234
	p	0.853	0.373	0.407	0.311	0.044	0.260

Pearson Correlation (r)

\*Correlation is significant  $\leq 0.05$  level (2-tailed).

\*\*Correlation is highly significant at  $\leq 0.01$  level (2-tailed).

**Table (V) :** Correlations between changes of lung comets score (absolute change, percentage changes) and IVCD changes (absolute change, percentage changes) and ultrafiltration volume

		Lung comets score absolute change	Lung comets score percentage change	Ultrafiltration volume (UF)
IVCD Absolute change	r	0.228	-0.003	0.305
	p	0.362	0.990	0.219
IVCD percentage change	r	0.313	0.287	0.298
	p	0.207	0.248	0.230
Ultrafiltration volume (UF)	r	0.564**	-0.012	1
	p	0.003	0.955	

Pearson Correlation (r)

\*Correlation is significant  $\leq 0.05$  level (2-tailed).

\*\*Correlation is highly significant at  $\leq 0.01$  level (2-tailed).

**Table (VI) :** Correlation between ultrasound lung comets and inferior vena cava diameter

		ULCs score before dialysis	ULCs score After dialysis	ULCs grade before dialysis	ULCs grade after dialysis	ULCs score percentage change	ULCs Score absolute change
IVCD before dialysis	r	0.432	0.552*	0.650**	0.688**	0.496*	-0.0164
	p	0.073	0.018	0.004	0.002	0.036	0.514
IVCD after dialysis	r	0.359	0.557*	0.559*	0.652**	0.628**	-0.013
	p	0.143	0.016	0.016	0.003	0.005	0.960
IVCD percentage change	r	-0.152	0.007	-0.174	0.010	0.287	0.313
	p	0.548	0.979	0.491	0.969	0.248	0.207
IVCD absolute change	r	-0.221	-0.169	-0.310-	-0.258	-0.003	0.228
	p	0.378	0.503	0.210	0.302	0.990	0.362

Pearson Correlation (r)

\*Correlation is significant  $\leq 0.05$  level (2-tailed).

\*\*Correlation is highly significant at  $\leq 0.01$  level (2-tailed).



GLOBAL JOURNAL OF MEDICAL RESEARCH: B  
PHARMA, DRUG DISCOVERY, TOXICOLOGY & MEDICINE  
Volume 16 Issue 3 Version 1.0 Year 2016  
Type: Double Blind Peer Reviewed International Research Journal  
Publisher: Global Journals Inc. (USA)  
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Copper (II) Oxide Nanoparticles Induce High Toxicity in Human Neuronal Cell

By Abudayyak Mahmoud, Guzel E. Elif & Özhan Gül

*Istanbul University*

**Abstract-** Copper (II) oxide nanoparticles (CuO-NPs) are widely used in industry, cosmetics and medicine. People have increasingly been exposed to these active materials. Several studies indicate that CuO-NPs could be taken up by different organs and cause toxicities. However, there is still a lack of data on the toxicological effects of CuO-NPs in neuronal system. In the present study, the toxic potentials of CuO-NPs were investigated in human SH-SY5Y neuroblastoma cells. After assessment of their cellular uptake potential, cytotoxicity by MTT and neutral red uptake (NRU) and genotoxicity by comet assay were evaluated. Enzyme-Linked Immune Sorbent Assays (ELISA) determination of malondialdehyde (MDA), 8-hydroxy-deoxyguanosine (8-OHdG), protein carbonyl (PC), and glutathione (GSH) levels for oxidative damage, and Annexin V-FITC with propidium iodide (PI) for apoptosis were used. In conclusion, CuO-NPs were found to accumulate in the cells and induced significant cytotoxic and genotoxic, and oxidative and apoptotic effects. CuO-NPs are hypothesized to dangerously affect human health, especially neuronal system.

**Keywords:** copper oxide; nanoparticle; neurotoxicity; cellular uptake; genotoxicity; apoptosis.

**GJMR-B Classification :** NLMC Code: QV 600



*Strictly as per the compliance and regulations of:*



# Copper (II) Oxide Nanoparticles Induce High Toxicity in Human Neuronal Cell

Abudayyak Mahmoud <sup>α</sup>, Guzel E. Elif <sup>σ</sup> & Özhan Gül <sup>ρ</sup>

**Abstract-** Copper (II) oxide nanoparticles (CuO-NPs) are widely used in industry, cosmetics and medicine. People have increasingly been exposed to these active materials. Several studies indicate that CuO-NPs could be taken up by different organs and cause toxicities. However, there is still a lack of data on the toxicological effects of CuO-NPs in neuronal system. In the present study, the toxic potentials of CuO-NPs were investigated in human SH-SY5Y neuroblastoma cells. After assessment of their cellular uptake potential, cytotoxicity by MTT and neutral red uptake (NRU) and genotoxicity by comet assay were evaluated. Enzyme-Linked Immune Sorbent Assays (ELISA) determination of malondialdehyde (MDA), 8-hydroxy-deoxyguanosine (8-OHdG), protein carbonyl (PC), and glutathione (GSH) levels for oxidative damage, and Annexin V-FITC with propidium iodide (PI) for apoptosis were used. In conclusion, CuO-NPs were found to accumulate in the cells and induced significant cytotoxic and genotoxic, and oxidative and apoptotic effects. CuO-NPs are hypothesized to dangerously affect human health, especially neuronal system. However, further studies should be done to elucidate their toxic mechanism.

**Keywords:** copper oxide; nanoparticle; neurotoxicity; cellular uptake; genotoxicity; apoptosis.

## I. INTRODUCTION

CuO-NPs are widely used in gas sensors, catalysts, high temperature conductors, solar energy converters and antimicrobial agents owing to their high temperature conductivity, electron correlation effects, antimicrobial activity and special physicochemical properties in various fields (Chang et al., 2012; Huang et al., 2010). Indeed, as it is well known, nanoparticles exist as contaminants in water, air and food products as outputs of natural phenomena or due to the high increase in the anthropogenic activity (Ahamed et al., 2013; Elsaesser et al., 2011; Kim et al., 2010). CuO-NPs caused changes in different organs like lung, kidney, renal tubular, liver, spleen, gastrointestinal tract and stomach tissue (Barceloux, 1999; Cho et al., 2012; Lei et al., 2008; Manna et al., 2012). Acute death,

*Author α:* Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Istanbul University, Istanbul-Turkey, Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Karadeniz Technical University, Trabzon-Turkey. e-mail: abudiak1987@yahoo.com

*Author σ:* Department of Histology and Embryology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul-Turkey. e-mail: elifguzelctf@yahoo.com

*Author ρ:* Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Istanbul University, Istanbul-Turkey, Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Beyazit 34116, Istanbul, Turkey. e-mail: gulozhan@istanbul.edu.tr

abnormalities in the embryo and gill damage were observed in Zebra fish exposed to CuO-NPs (Griffitt et al., 2007; Yeo et al., 2009). The toxicity studies of CuO-NPs have been focused more generally on the pulmonary system and to a lesser extent on skin, breast, intestine and liver (Ahamed et al., 2010; Akhtar et al., 2012; An et al., 2012; Cuillel et al., 2014; Laha et al., 2014; Piret et al., 2012; Siddiqui et al., 2013; Sun et al., 2011; Wang et al., 2011). However, there are few reports on the nervous system (An et al., 2012; Chen et al., 2008; Perreault et al., 2012). Therefore, it was aimed to evaluate the toxicity and possible mechanism of action of CuO-NPs in neuroblastoma cells following their cellular uptake potential.

## II. MATERIALS AND METHODS

**Chemicals:** Eagle's minimum essential medium (EMEM), fetal bovine serum (FBS), phosphate buffered saline (PBS, 10X), antibiotic solutions and ethylene diamine tetraacetic acid (EDTA) were purchased from Multicell Wisent (Quebec, Canada). Triton X-100 and MTT(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) were purchased from Biomatik (Ontario, Canada). GSH, 8-OHdG, MDA and PC ELISA kits were purchased from Yehua Biological Technology Co., Ltd. (Shanghai, China). Annexin V-FITC apoptosis detection kit with PI and dye reagents for protein assay were obtained from Exbio (Vestec, Czech Republic) and Bi-rad (Munich, Germany), respectively. All other chemicals were obtained from Merck (NJ, USA).

CuO-NPs were obtained from Sigma Chemical Co. Ltd. (St. Louis, MO, USA). The CuO-NPs suspensions in milli-Q water and cell culture medium with 10% FBS, were measured by Transmission Electron Microscopy (TEM) (Jem-2100 HR, Jeol, USA) (Abudayyak et al. 2016; 2016a). The average diameter was calculated by measuring over 100 particles in random fields of TEM view.

**Copper release into cell medium:** Copper release from CuO-NPs into the cell culture medium was determined using the Inductively Coupled Plasma Mass Spectrometry (ICP-MS) (Thermo Elemental X series 2, USA) method (Abudayyak et al. 2016; 2016a). The released amount of copper was analyzed by ICP-MS. Cu content of the cell culture medium was also measured.

**Cell culture conditions:** Human neuronal cell line (SH-SY5Y) was obtained from the American Type Culture

Collection (CRL-2266™, ATCC, VA, USA). The cells were incubated in EMEM medium supplemented with FBS 10% and antibiotics at 5% CO<sub>2</sub>, 90% humidity and 37°C for 24 h (60-80% confluence). Cell densities were in the range from 1 × 10<sup>5</sup> to 1 × 10<sup>7</sup> cells/mL for all assays (Abudayyak et al. 2016; 2016a). Exposure occurred for 24 h.

*Cellular uptake and morphology examinations:* It was evaluated by ICP-MS and TEM (Abudayyak et al. 2016; 2016a). The cells were washed several times with equal volumes of PBS and cell culture medium with 10% FBS and counted via Luna cell counter (Virginia, USA) following exposure to two different concentrations of the particle suspension (2.5 and 25 μg/mL). Ultra-thin sections (50-60 nm) were cut by an ultra-microtome (Reichert UM 3, Austria). Sections were analyzed and photographed using a TEM (Jeol-1011, Tokyo, Japan) with attached digital camera (Olympus-Veleta TEM Camera, Tokyo, Japan).

*Cytotoxicity assays:* Cytotoxic activities of CuO-NPs on SH-SY5Y cells were determined by MTT and NRU assays based on different cellular mechanisms (Abudayyak et al. 2016; 2016a; Repetto et al., 2008; Van Meerloo et al., 2011). Optical density (OD) values were read at 590 and 540 nm for MTT and NRU, respectively, using a microplate spectrophotometer system (Epoch, Germany). In every assay, unexposed cells were served as a negative control. The inhibition of enzyme activity was calculated as compared to a negative control. The half-maximal inhibitory concentration (IC<sub>50</sub>) was then expressed as the concentration of the sample causing a 50% inhibition of enzyme activity in cells. The CuO-NP concentrations were 2.5-60 μg/mL in the cytotoxicity assays.

*Genotoxicity assay:* Genotoxic activities of CuO-NPs were determined by comet assay (Abudayyak et al. 2016; 2016a; Collins et al., 2004; Speit et al., 1999). Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) (100 μM) and PBS were used as positive and negative controls, respectively. The number of DNA breaks was scored under a fluorescent microscope (Olympus BX53, Olympus, Tokyo, Japan) at 400X magnification using an automated image analysis system (Comet Assay IV, Perceptive Instruments, Suffolk, UK). DNA damage to individual cells was expressed as a percentage of DNA in the comet tail (tail intensity %). The CuO-NP concentrations were 5-50 μg/mL in the comet assay.

*Oxidative damage assays:* The oxidative damage potentials of CuO-NPs were measured by human GSH, MDA, 8-OHdG, or PC ELISA kits with different endpoints according to the manufacturer's instructions. The OD value was read at 450 nm using a microplate spectrophotometer system. In every assay, the unexposed cells served as a negative control. The protein amount in 10<sup>6</sup> cells was measured according to Bradford (1976). Results were expressed as μmol, μmol,

μg, and μg per g protein for GSH, MDA, 8-OHdG, and PC, respectively, using a standard calibration curve. The CuO-NP concentrations were 5-25 μg/mL in the oxidative damage assays.

*Apoptosis assay:* The cellular apoptosis or necrosis was determined by Annexin V-FITC apoptosis detection kit with PI (Abudayyak et al. 2016; 2016a). In every assay, the untreated cells served as a negative control. The results were expressed as a percentage of the total cell amount. The CuO-NP concentrations were 10-80 μg/mL in the apoptosis assay.

*Statistical analysis:* The assays were done in triplicate and repeated four times. Data were expressed as mean ± standard deviation (SD). Significant differences between untreated and treated cells were calculated by one-way ANOVA Dunnett t-test using SPSS version 17.0 for Windows. *p* values of less than 0.05 were considered significant.

### III. RESULTS AND DISCUSSION

*Particle size and distribution:* According to the X-ray diffraction results supplied by the manufacturer (Sigma Chemical Co. Ltd., USA), the surface area of CuO-NPs was 29 m<sup>2</sup>/g (Figure 1). The average size was observed to be 34.9 nm with a narrow size distribution (ranging from 16.7-64.2 nm) after suspending in water. When suspending in the culture medium, the size of the particles was found to be slightly agglomerated and/or aggregated with 38.8 nm (ranging from 18.8-73.8 nm) (Figure 2). The copper ion release of CuO-NPs was evaluated in the cell culture medium. Although the concentration was 3.1 ± 0.322 μg/mL, which represented 15.5% of the nanoparticles, in the CuO-NPs cell culture suspension, there was no observed copper ions in the cell culture medium. Based on that, the observed toxicological endpoints and morphological changes were mainly due to CuO-NPs.

*Cellular uptake:* ICP-MS revealed that the particles were taken up by SH-SY5Y cells in the range of 0.390-0.917 μg/10<sup>5</sup> cells in concentration dependent manner following exposure to CuO-NPs at 5-25 μg/mL concentrations (Table 1). Some researchers reported iron oxide and two different types of titanium dioxide nanoparticles to enter SH-SY5Y cells in concentration dependent manner (Kilic et al., 2016; Valdiglesias et al., 2013).

*Cellular morphology by TEM:* The particles were observed in the cytoplasmic vacuoles. Mitochondria were visible in few of the cells exposed to both 2.5 and 10 μg/mL CuO-NPs. Some cells exposed to 2.5 μg/mL CuO-NPs revealed nuclear fragmentation. The electron-lucent cytoplasmic vacuoles lead to complete disruption of the cytoplasm in few of the cells (Figure 3).

*Cytotoxicity:* IC<sub>50</sub> values of CuO-NPs were 25.49 ± 2.06 and 7.27 ± 0.843 μg/mL by MTT and NRU assay,

respectively. The reduction in cell viability was concentration-dependent (Figure 4). The CuO-NPs were found to cause cytotoxic effects to HaCaT keratinocytes, BALB3T3 embryonic fibroblasts (Akhtar et al., 2012; Kilic et al., 2016), HepG2 (Siddiqui et al., 2013; Wang et al., 2011), A549 lung epithelial (Karlsson et al., 2008; Wang et al 2012), HEp-2 airway epithelial (Wang et al 2012), Caco-2 intestinal (Piret et al., 2012), cardiac microvascular endothelial cells (Sun et al., 2011) and primary culture of channel catfish hepatocytes (Wang et al., 2011). Perreault et al. (2012) found mouse N2A neuroblastoma cell viability decreased to 63% at 400  $\mu\text{g}/\text{mL}$  for 24 h. Chen et al. (2008) reported CuO-NPs showed the cytotoxic effect in SH-ST5Y neuroblastoma and H4 neuroglioma cells were dose-dependent. It caused a drop of 60 and 40% in live cell percentages in SH-ST5Y and H4 cells, respectively, at 100  $\mu\text{M}$  concentration.

**Genotoxicity:** In positive controls (100  $\mu\text{M}$   $\text{H}_2\text{O}_2$ ), the tail intensity was 21.43%. The results revealed that CuO-NPs significantly induced DNA damage in all exposure concentrations (2.57-7.09 fold) and generally in dose dependent manner ( $p \leq 0.05$ ). The highest tail intensity was 24.09 observed at a concentration of (15  $\mu\text{g}/\text{mL}$ ). The cell death was  $\leq 50\%$  in all concentrations (Figure 5). CuO-NPs induced genotoxic responses in A549 (Ahamed et al., 2010; Akhtar et al., 2016; Cronholm et al., 2011; Wang et al., 2012) and BEAS-2B lung epithelial cells (Cronholm et al., 2011). Perreault et al. (2012) found CuO-NPs significantly induced DNA damage in mouse N2A neuroblastoma cells at 12.5  $\mu\text{g}/\text{mL}$ . Researchers suggested CuO-NPs induced DNA damage significantly correlated with reactive oxygen species (ROS) (Akhtar et al., 2016). Also, it could be via disruption of cell membrane integrity (Cronholm et al., 2011). However, there was no study about genotoxicity on SH-SY5Y cells.

**Oxidative damage:** The oxidative damage potential of CuO-NPs was evaluated by measuring cellular levels of GSH, MDA, 8-OHdG, and PC (Table 2). CuO-NPs induced oxidative damage resulting in significant decrease in the GSH levels ( $\leq 46.1\%$ ). Although an increase on the levels of MDA ( $\leq 1.33$  fold) was observed it was not significant. On the other hand, the levels of PC and 8-OHdG protein and DNA oxidative damage biomarkers did not change. In previous studies, it was observed that CuO-NPs induced oxidative damage in HaCaT keratinocytes (Alarifi et al., 2013), BALB3T3 fibroblasts (Akhtar et al., 2012), A549, (Ahamed et al., 2010; Akhtar et al., 2013; Karlsson et al., 2008; Kim et al., 2010), HEp-2 (Fahmy and Cormier, 2009), and HepG2 cells (Piret et al., 2012; Siddiqui et al., 2013). The reduction in cell viability observed could be due to an increase in oxidative stress after CuO-NPs exposure.

**Apoptosis:** Death in SH-SY5Y cells was significantly induced by CuO-NPs, with a maximum percentage of 73.4 and 40.0% for apoptosis and necrosis, respectively. According to our results, apoptosis was seen to be the main pathway for cell death in the SH-SY5Y cell line. At the highest exposure concentration (40  $\mu\text{g}/\text{mL}$ ), the apoptosis percentage was 79.2% of the dead cells (Figure 6). The previous studies showed CuO-NPs could induce apoptosis in the following cells: MCF7 breast cancer (Laha et al., 2014), HepG2 (Siddiqui et al., 2013), and Caco-2 cells (Piret et al., 2012). In rats, CuO-NPs induced apoptosis via increased cleaved caspase-3 levels (An et al., 2012). Siddiqui et al. (2013) observed CuO-NPs induced apoptosis via a decrease in mitochondrial membrane potential with a concomitant increase in the gene expression ratio of Bax/Bcl2, up-regulation of p53 tumour suppressor and caspase-3 apoptotic genes. Also, the researchers showed apoptosis could be induced by reduction of BAD phosphorylation and an increase in cleaved caspase-3 products (Laha et al., 2014). An et al. (2012) indicated that the apoptosis and cognitive impairment could be via increased cleaved caspase-3 levels on hippocampal CA1 neuron in rats.

#### IV. CONCLUSION

Generally, the studies about Cu based nanoparticles and CuO-NPs were focused on the pulmonary system. However, very few researchers were concerned about the possible toxicity over other systems. In the present study, it was observed that CuO-NPs taken up by the neuronal cells could produce cytotoxic, genotoxic, and apoptotic effects, as well as oxidative damage in the neuronal cells *in vitro*. Their commercial and industrial applications should be carefully evaluated because of their potential hazardous effects on human health. Further *in vivo* studies are needed to fully understand the toxicity mechanisms of CuO-NPs.

#### V. ACKNOWLEDGEMENT

This work was supported by the Research Fund of Istanbul University (Project No: 52253). Dr. M. Abudayyak carried out cell culture and exposure conditions, the toxicological assays and the particle characterisation. Prof. Dr. G. Özhan participate the toxicological assays and carried out the evaluation of the results. Dr. E. Guzel carried out the uptake and morphological changes in the cells. All authors wrote, read and approved the manuscript. Also, the authors declare there is no conflict of interest.

#### REFERENCES RÉFÉRENCES REFERENCIAS

1. Ahamed M, Ali D, Alhadlaq HA, et al. 2013. Nickel oxide nanoparticles exert cytotoxicity via oxidative



- stress and induce apoptotic response in human liver cells (HepG2). *Chemosphere* **93**: 14-22.
2. Abudayyak M, Altincekic T, Özhan G. 2016. In vitro toxicological evaluation of cobalt ferrite nanoparticles. *Biol. Trace Element Res.* Doi: 10.1007/s12011-016-0803-3.
  3. Abudayyak M, Guzel EE, Özhan G. 2016a. Copper (II) oxide nanoparticles induced nephrotoxicity in vitro conditions. *Appl. Vitro Toxicol.* Doi:10.1089/aivt.2016.0008.
  4. Ahamed M, Siddiqui MA, Akhtar MJ, et al. 2010. Genotoxic potential of copper oxide nanoparticles in human lung epithelial cells. *Biochem. Biophys. Res. Commun.* **396**: 578-583.
  5. Akhtar MJ, Ahamed M, Fareed M, et al. 2012. Protective effect of sulphoraphane against oxidative stress mediated toxicity induced by CuO nanoparticles in mouse embryonic fibroblasts BALB 3T3. *J. Toxicol. Sci.* **37**(1):139-148.
  6. Akhtar MJ, Kumar S, Alhadlaq HA, et al. 2016. Dose-dependent genotoxicity of copper oxide nanoparticles stimulated by reactive oxygen species in human lung epithelial cells. *Toxicol. Ind. Health* **32**(5):809-821.
  7. Alarifi S, Ali D, Verma A, et al. 2013. Cytotoxicity and genotoxicity of copper oxide nanoparticles in human skin keratinocytes cells. *Int. J. Toxicol.* **32**(4): 296-307.
  8. An L, Liu S, Yang Z, et al. 2012. Cognitive impairment in rats induced by nano-CuO and its possible mechanisms. *Toxicol. Lett.* **213**(2): 220-227.
  9. Barceloux DG. 1999. Copper. *J. Toxicol. Clin. Toxicol.* **37**: 217-237.
  10. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **7**: 248-254.
  11. Chang YN, Zhang M, Xia L, et al. 2012. The toxic effects and mechanisms of CuO and ZnO nanoparticles. *Materials* **5**: 2850-2871.
  12. Chen J, Zhu J, Cho H-H, et al. 2008. Differential cytotoxicity of metal oxide nanoparticles. *J. Exp. Nanosci.* **3**: 321-328.
  13. Cho WS, Duffin R, Poland CA, et al. 2012. Differential pro-inflammatory effects of metal oxide nanoparticles and their soluble ions in vitro and in vivo; zinc and copper nanoparticles, but not their ions, recruit eosinophils to the lungs. *Nanotoxicol.* **6**: 22-35.
  14. Collins AR. 2004. The comet assay for DNA damage and repair principles, applications, and limitations. *Mol. Biotechnol.* **26**: 249-261.
  15. Cronholm P, Midander K, Karlsson HL, et al. 2011. Effect of sonication and serum proteins on copper release from copper nanoparticles and the toxicity towards lung epithelial cells. *Nanotoxicol.* **5**(2): 269-281.
  16. Cuillel M, Chevallet M, Charbonnier P, et al. 2014. Interference of CuO nanoparticles with metal homeostasis in hepatocytes under sub-toxic conditions. *Nanoscale* **6**(3): 1707-1715.
  17. Elsaesser A, Howard CV. 2011. Toxicology of nanoparticles. *Adv. Drug Deliv Rev* **64**: 129-37.
  18. Fahmy B, Cormier SA. 2009. Copper oxide nanoparticles induce oxidative stress and cytotoxicity in airway epithelial cells. *Toxicol. in Vitro* **23**(7): 1365-1371
  19. Griffitt RJ, Weil R, Hyndman KA, et al. 2007. Exposure to copper nanoparticles causes gill injury and acute lethality in zebrafish (*Danio rerio*). *Environ. Sci. Technol.* **41**: 8178-8186.
  20. Huang YW, Wu CH, Aronstam RS. 2010. Toxicity of transition metal oxide nanoparticles: Recent insights from in vitro studies. *Materials* **3**: 4842-4859.
  21. Karlsson HL, Cronholm P, Gustafsson J, et al. 2008. Copper oxide nanoparticles are highly toxic: a comparison between metal oxide nanoparticles and carbon nanotubes. *Chem. Res. Toxicol.* **21**(9): 1726-1732.
  22. Kilic G, Costa C, Fernández-Bertólez N, et al. 2016. In vitro toxicity evaluation of silica-coated iron oxide nanoparticles in human SHSY5Y neuronal cells. *Toxicol. Res.* **5**: 235-247.
  23. Kim YJ, Yu M, Park HO, et al. 2010. Comparative study of cytotoxicity, oxidative stress and genotoxicity induced by silica nanomaterials in human neuronal cell line. *Mol. Cell. Toxicol.* **6**: 337-344.
  24. Laha D, Pramanik A, Maity J, et al. 2014. Interplay between autophagy and apoptosis mediated by copper oxide nanoparticles in human breast cancer cells MCF7. *Biochim. Biophys. Acta* **1840**: 1-8.
  25. Lei R, Wu C, Yang B, et al. 2008. Integrated metabolomic analysis of the nano-sized copper particle-induced hepatotoxicity and nephrotoxicity in rats: a rapid in vivo screening method for nanotoxicity. *Toxicol. Appl. Pharmacol.* **232**(2): 292-301.
  26. Manna P, Ghosh M, Ghosh J, et al. 2012. Contribution of nano-copper particles to in vivo liver dysfunction and cellular damage: role of I $\kappa$ B $\alpha$ /NF- $\kappa$ B, MAPKs and mitochondrial signal. *Nanotoxicol.* **6**: 1-21.
  27. Perreault F, Melegari SP, de Costa CH, et al. 2012. Genotoxic effects of copper oxide nanoparticles in Neuro 2A cell cultures. *Sci. Total Environ.* **441**: 117-124.
  28. Piret JP, Jacques D, Audinot JN, et al. 2012. Copper (II) oxide nanoparticles penetrate into HepG2 cells, exert cytotoxicity via oxidative stress and induce pro-inflammatory response. *Nanoscale* **4**: 7168-7184.

29. Repetto G, del Peso A, Zurita JL 2008. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. *Nature Protocols* **3**: 1125-1131.
30. Siddiqui M, Alhadlaq HA, Ahmad J, et al. 2013. Copper oxide nanoparticles induced mitochondria mediated apoptosis in human hepatocarcinoma cells. *PloS One* **8**(8): e69534.
31. Speit G, Hartmann A. 1999. The comet assay (single-cell gel test): A sensitive genotoxicity test for the detection of DNA damage and repair. *DNA Repair Protocols* **113**: 203-212.
32. Sun J, Wang S, Zhao D, et al. 2011. Cytotoxicity, permeability, and inflammation of metal oxide nanoparticles in human cardiac microvascular endothelial cells. *Cell Biol. Toxicol.* **27**(5): 333-342.
33. Valdiglesias V, Costa C, Sharma V, et al. 2013. Comparative study on effects of two different types of titanium dioxide nanoparticles on human neuronal cells. *Food Chem. Toxicol.* **57**: 352-61.
34. Van Meerloo J, Kaspers GJ, Cloos J. 2011. Cell sensitivity assays: The MTT assay. *Methods Mol. Biol.* **731**: 237-245.
35. Wang Y, Aker WG, Hwang H, et al. 2011. A study of the mechanism of in vitro cytotoxicity of metal oxide nanoparticles using catfish primary hepatocytes and human HepG2 cells. *Sci. Total Environ.* **409**: 4753-4762.
36. Wang Z, Li N, Zhao J, et al. 2012. CuO nanoparticle interaction with human epithelial cells: cellular uptake, location, export, and genotoxicity. *Chem. Res. Toxicol.* **25**(7): 1512-1521.
37. Yeo MK, Kang M. 2009. Effects of Cu<sub>2</sub>TiO<sub>4</sub> nanometer particles on biological toxicity during zebrafish embryogenesis. *Korean J. Chem. Eng.* **26**: 711-718.




Figure 1 : The X-ray diffraction analysis of CuO-NPs.






Figure 2 : The TEM images and size distributions of CuO-NPs after dissolution in water (a) and cell culture medium (b).



**Figure 3 :** TEM observations of SH-SY5Y cells after exposure to CuO-NPs. (a) cells exposed to CuO-NPs at 2.5  $\mu\text{g/mL}$ ; (b) cells exposed to CuO-NPs at 10  $\mu\text{g/mL}$ ; (c) unexposed cell (negative control).



**Figure 4 :** Effects of CuO-NPs on SH-SY5Y cell viability.




Figure 5 : Evaluation of DNA damage potential of CuO-NPs in SH-SY5Y cells.

All experiments were done in triplicate and each assay was repeated four times.

The results were expressed as the mean cell death (%) compared to negative control (unexposed cell).





Figure 6 : Evaluation of the apoptosis- and necrosis-inducing potential of CuO-NPs in SH-SY5Y cells.

All experiments were done in triplicate and each assay was repeated four times.

The results were presented as mean tail intensity (%) with ± SD, NC and PC mean negative and positive controls, respectively.

\* $p \leq 0.05$  were selected as the levels of significance by one-way ANOVA Dunnett t-test.



All experiments were done in triplicate and each assay was repeated four times.

The results were presented as percentages of the total cell amount.

*Table 1* : Evaluation of the cellular uptakes of CuO-NPs from SH-SY5Y cells.

Exposure concentration (µg/mL/10 <sup>5</sup> cells)	Cu amount (µg/10 <sup>5</sup> cells)
Negative control	0.0137±0.002
5	0.390±0.051
10	0.378±0.076
15	0.641±0.062
25	0.917±0.980

Cu content of the negative control (unexposed cell) was also measured. Every assay was repeated four times. The results were expressed as mean ± SD.

*Table 2* : Evaluation of oxidative damage potentials of CuO-NPs in SH-SY5Y cells.

Exposure concentration (µg/mL)	GSH (µmol/g protein)	MDA (µmol/g protein)	8-OHdG (µg/g protein)	PC (µg/g protein)
0	46.796±0.952	0.320±0.086	6.777±0.0988	0.916±0.019
5	30.514±1.319*	0.280±0.092	5.870±0.529	0.747±0.057
10	25.247±1.072*	0.350±0.064	6.287±0.418	0.807±0.120
15	32.160±1.491*	0.416±0.108	6.576±0.246	0.866±0.109
25	34.884±1.220*	0.425±0.156	6.836±0.098	0.805±0.088

The protein amount calculated for 4x10<sup>4</sup> cells in every assay according to Bradford (1976).

The results were expressed as µmol, µmol, µg and µg per g protein for GSH, MDA, 8-OHdG and PC, respectively, using standard calibration curve.

\**p* ≤ 0.05 were selected as the levels of significance.



GLOBAL JOURNAL OF MEDICAL RESEARCH: B  
PHARMA, DRUG DISCOVERY, TOXICOLOGY & MEDICINE  
Volume 16 Issue 3 Version 1.0 Year 2016  
Type: Double Blind Peer Reviewed International Research Journal  
Publisher: Global Journals Inc. (USA)  
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## The Relation of Serum High-Sensitive C- Reactive Protein to Serum Lipid Profile, Vitamin D and Other Variables in a Group of Hypertensive Patients in Erbil-Iraq

By Salam Naser Zangana

*Hawler Medical University*

**Abstract- Background and objectives:** Hypertension is an established risk factor for atherosclerosis. Elevated levels of high-sensitive C-reactive protein (hs-CRP) were detected in hypertensive patients. Recent studies suggest a link between high-sensitive C-reactive protein (hs-CRP) and atherosclerosis in hypertension. Growing evidence suggests that vitamin D affects the cardiovascular system. The objective of this study was to assess the relationship of hs-CRP to lipid profile, vitamin D and other variables in hypertensive patients in Erbil-Iraq.

**Subjects and Methods:** This cross-sectional study was conducted on two-hundred adults (130 hypertensives and 70 normotensives). The participants were classified into three groups according to their BP measurements as normotensive (group I), stage I hypertension (group II) and stage II hypertension (group III). Serum hs-CRP, lipid profile, vitamin D levels, and other variables were evaluated in all studied groups.

**Keywords:** *Hs-CRP, hypertension, lipid profile, vitamin D.*

**GJMR-B Classification :** *NLMC Code: WG 340*



*Strictly as per the compliance and regulations of:*



# The Relation of Serum High-Sensitive C- Reactive Protein to Serum Lipid Profile, Vitamin D and Other Variables in a Group of Hypertensive Patients in Erbil-Iraq

Salam Naser Zangana

**Abstract- Background and objectives:** Hypertension is an established risk factor for atherosclerosis. Elevated levels of high-sensitive C-reactive protein (hs-CRP) were detected in hypertensive patients. Recent studies suggest a link between high-sensitive C-reactive protein (hs-CRP) and atherosclerosis in hypertension. Growing evidence suggests that vitamin D affects the cardiovascular system. The objective of this study was to assess the relationship of hs-CRP to lipid profile, vitamin D and other variables in hypertensive patients in Erbil-Iraq.

**Subjects and Methods:** This cross-sectional study was conducted on two-hundred adults (130 hypertensives and 70 normotensives). The participants were classified into three groups according to their BP measurements as normotensive (group I), stage I hypertension (group II) and stage II hypertension (group III). Serum hs-CRP, lipid profile, vitamin D levels, and other variables were evaluated in all studied groups.

**Results:** Hs-CRP level was significantly higher in hypertensives as compared to normotensives ( $P < 0.001$ ). The means of total cholesterol (TC), triglyceride (TG) and low-density lipoprotein (LDL) were significantly higher, while the mean of high-density lipoprotein (HDL) was significantly lower in hypertensives than in normotensives ( $P < 0.001$ ). The mean of vitamin D was significantly lower in hypertensives than in normotensives ( $P < 0.001$ ). Hs-CRP was positively correlated with TC, TG, and LDL but inversely correlated with HDL and vitamin D.

**Conclusions:** Higher levels of hs-CRP were detected in hypertensive patients than normotensives. The higher hs-CRP levels were significantly correlated with higher grades of hypertension. Hs-CRP was positively correlated with lipid profile and inversely correlated with vitamin D. Increased levels of hs-CRP in hypertension may suggest a role of inflammation in hypertension. Hs-CRP estimation may be recommended in evaluation of all hypertensive patients.

**Keywords:** Hs-CRP, hypertension, lipid profile, vitamin D.

## I. INTRODUCTION

Hypertension is an established major independent risk factor for development of atherosclerosis and multiple cardiovascular diseases worldwide.<sup>1</sup> According to the 2006 Iraqi national survey for chronic disease risk factors, 40.4% of the Iraqi adult populations

*Author: M.B.Ch.B., D.M., C.A.B.M.S., F.I.C.M.S. Senior Lecturer, Department of Medicine, College of Medicine, Hawler Medical University, Erbil-Iraq. e-mail: dr\_salam2003@yahoo.com*

have elevated blood pressure.<sup>2</sup> Many recent studies correlate between hypertension and inflammation.<sup>3</sup> New proof indicates that vascular inflammation may have a role in the initiation and /or development of hypertension.<sup>4</sup> Several researchers have noticed higher high-sensitive C-reactive protein (hs-CRP) levels in patients with hypertension.<sup>5</sup> Vitamin D deficiency or insufficiency is a common condition that affects up to one-half of otherwise healthy middle aged to elderly population.<sup>6</sup> Although vitamin D deficiency involves mainly musculoskeletal system, growing evidence suggests that vitamin D affects the cardiovascular system also.<sup>7</sup>

High concentrations of CRP might reduce nitric oxide production in endothelial cells, leading to vasoconstriction and increase blood pressure. Endothelial dysfunction and inflammation were associated with arterial stiffness.<sup>8</sup> Hs-CRP, an acute phase reactant protein, is a proinflammatory atherogenic marker which can be an early cardiac risk predictor.<sup>9</sup> A hs-CRP test measures low levels of CRP using laser nephelometry. The test gives a sensitivity results down to 0.04 mg/L. The American Heart Association and U.S. Centers for Disease Control and Prevention have defined risk groups as follows: low: hs-CRP level under 1.0 mg/L, average: between 1.0 and 3.0 mg/L, and high: above 3.0 mg/L.<sup>10,11</sup>

To date, and up to our knowledge, there was no previous study done regarding the same subject in Erbil city. The objective of this study was to assess the correlation between hs-CRP levels to serum lipid profile and other variables in a group of hypertensive patients in Erbil city-Iraq.

## II. PATIENTS AND METHODS

This cross-sectional study was conducted in Rizgary teaching hospital between July 2015 and July 2016. A total of 200 participants (130 participants with essential hypertension and additional 70 normotensives, as control group) were enrolled in the study. According to blood pressure (BP) measurements, The participants were classified into three groups; Group I (normotensive participants, SBP  $\leq$  120 mmHg, and /or DBP  $\leq$  80

mmHg, n=70), group II (stage 1 hypertension, SBP 140-159 mmHg, and /or DBP 90-99 mmHg, n=67) and group III (stage 2 hypertension, SBP $\geq$ 160 mmHg, and /or DBP $\geq$  100 mmHg, n= 63). All participants were assessed by a detailed history, physical examination, echocardiographic evaluation and other investigational tools. Blood samples were drawn to measure the hs-CRP, serum lipid profile and vitamin D level for each participant.

The inclusion criteria were patients with essential hypertension, age  $\geq$  18 years and of both genders.

The exclusion criteria were patients with secondary hypertension (diabetic nephropathy, polycystic kidney disease, renovascular hypertension), Cushing syndrome, thyroid disease, chronic renal failure, patients with primary hyperparathyroidism, malabsorption, osteomalacia or osteoporosis, patients on medications like anticonvulsants, glucocorticoids and vitamin D supplements.

BMI (Body Mass Index, weight/height<sup>2</sup>) was calculated according to a standard definition.<sup>12</sup>

Based on recommendations of the Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8)<sup>13</sup>, hypertension was defined as systolic blood pressure  $\geq$ 140 mmHg and diastolic blood pressure  $\geq$  90 mmHg for adults aged 18 years and less than 60 years, and systolic blood pressure  $\geq$  150 or diastolic  $\geq$  90 in general population  $\geq$  60 years. Blood pressure measurements used in this study were taken with a mercury sphygmomanometer. Measurements were made to the nearest 2mmHg, in the sitting position with the arm supported, and repeated after 5 minutes' rest if the first recording is high. We will take 2 measurements at each visit.

Transthoracic echocardiographic examinations were performed in the left lateral position. Standard M-mode, 2-Dimensional and Doppler echocardiographies were performed using (Brand GE Vivid E9 -2009) echocardiography machine. LV end-diastolic diameter (LVDd), LV end-systolic diameter(LVSd), left atrial (LA) and all other diameters were measured according to established standards of the American Society of Echocardiography.<sup>14</sup> LV mass (LVM) were calculated according to the Devereux formula<sup>15</sup>:  $LVM=1.04[(LVDd + IVSth +PWT)^3 - (LVDd)^3] -13.6$ . Thereafter, LV mass index(LVMI) was obtained by the following formula:  $LVM/body\ surface\ area\ (g/m^2)$ <sup>16</sup>. In the presence of LVH, the LVM exceeds 134 grams in men and 110 grams in women per meter square body surface area (m<sup>2</sup> BSA).

Although a consensus regarding the optimal level of serum 25(OH) D has not yet been established, most experts define vitamin D deficiency as a 25(OH) D level of <20 ng/ml, vitamin D insufficiency as 21 to 29 ng/ml and the optimal concentration of 25(OH) D is at least 30 ng/ml.<sup>17</sup>

Estimation of serum lipid profile was done by using automated biochemistry analyzer and according to standard methods.<sup>18</sup>

Pulse pressure (PP) is the difference between the systolic and diastolic pressure readings (PP= SBP-DBP). It is measured in millimeters of mercury (mmHg). It represents the force that the heart generates each time it contracts.<sup>19</sup>

The mean arterial pressure (MAP) is a term used to describe an average blood pressure in an individual. It is defined as the average arterial pressure during a single cardiac cycle.<sup>19</sup>  $MAP=DBP+1/3\ PP$ .

The data were collected by interviewing the patients using a questionnaire designed by the researchers. The questionnaire included information about socio-demographic data (age, gender, marital status,...), hypertension, risk factors like hyperlipidemia, IHD, obesity, family history, others), and history of smoking and alcoholism.

*Ethical considerations:* The study protocol was approved by the ethics committee of the College of Medicine of Hawler Medical University. This study was conducted by using an informed verbal consent from the patients prior to participation in the study. The purpose of the study was carefully explained to each patient.

*Statistical analysis of data:* Data were analyzed using the statistical package for social sciences (SPSS, version 19). Student's t test for two independent samples was used to compare means. Correlation coefficient (r) was obtained to demonstrate the correlations between variables. A 'P' value  $\leq$  0.05 was considered as statistically significant.

### III. RESULTS

The age and BMI were matched in all three groups of the study (P =0.49 and 0.98, respectively). As expected, SBP, DBP, PP and MAP values were significantly higher in hypertensive groups as compared to normotensive group (P<0.001, for each). Statistically higher levels of TC, TG, LDL (P<0.001, for each) and lower level of HDL (P<0.001) were found in hypertensives than in normotensives. IVS, PW, LVM, LVMI and RWT levels were significantly higher (P <0.001, for each) in hypertensives as compared to normotensives. We found also that the mean of vitamin D level was significantly lower (7.61 ng/dl) and the mean of hs-CRP level was significantly higher (2.75 mg/dl) in hypertensives than normotensives (17.3 ng/dl and 0.74 mg/dl respectively) (P<0.001, for each), as shown in Table 1.

In Table 2, which compares between the two hypertensive groups and as expected, SBP, DBP, PP and MAP values were significantly higher (P<0.001, for each) in group III as compared to group II. There were no differences in both groups regarding serum lipid profile values (P=0.91, 0.87, 0.74 and 0.8 respectively),



the same applies to EF ( $P=0.85$ ). IVS, PW, LVM, LVMI, RWT and left atrium values were significantly higher in group III patients than in group II patients. Group III patients had significantly higher hs-CRP values (3.67 mg/dl) than group II patients (1.83 mg/dl) ( $P<0.001$ ). Although the mean value of vitamin D was lower (6.9 ng/dl) in group III patients than in group II patients (8.32 ng/dl), but it was not statistically significant ( $P=0.5$ ).

Hs-CRP correlated positively with SBP, DBP, PP, MAP, TC, TG, LDL, LVM, LVMI, and correlated negatively with HDL and vitamin D, as shown in Table 3.

#### IV. DISCUSSION

In the present study, hypertensive patients had higher hs-CRP levels than normotensives. This indicates that inflammation might be associated with hypertension. This is compatible with other studies. Ki Chul Sung et al<sup>20</sup> and Sesso et al<sup>21</sup> found a positive relation between increasing levels of hs-CRP and risk of developing hypertension. But Bautista et al<sup>22</sup> in 2003 didn't find such association.

CRP has been reported to decrease nitric oxide production<sup>8</sup> and increases endothelin-1 and plasminogen activator inhibitor-1 activity in endothelial cells<sup>23</sup> to induce vasoconstriction, platelet activation, and thrombosis. In addition, CRP has shown to up regulate angiotensin receptor-1 and thus enhancing angiotensin-II activity and this leads to rise in blood pressure.<sup>24</sup>

In our study, hypertensive patients had abnormal lipid profile and that was evident by the presence of high TC, TG and LDL levels and low HDL level. This is compatible with other studies. Rasouli M et al<sup>25</sup> found higher cholesterol and TG levels in hypertension. In the Strong Heart Study (2006)<sup>26</sup>, an abnormal lipid profile was found in hypertensive American Indian population. Marco et al<sup>27</sup> found that participants who were prehypertensives and later developed hypertension had higher levels of TG and lower HDL levels. All these data suggest that vascular inflammation plays a role in pathophysiology of hypertension and may exacerbate the pro-atherogenic effects of hypertension.

In our study, elevated hs-CRP levels were associated with high PP. This result is compatible with Abramson et al<sup>28</sup> study which found such a positive association. Recent studies emphasize the possibility that arterial stiffening may precede the development of hypertension. Arterial stiffening was associated with many circulating inflammatory markers suggesting that inflammation may play a role in arterial stiffness.<sup>29</sup> If the blood vessel becomes rigid in conditions such as arteriosclerosis or atherosclerosis, the pulse pressure would be very high. Some evidence suggests that pulse pressure is a better predictor of clinical outcome than the systolic or diastolic blood pressure alone. Several

studies have identified that high pulse pressure causes more artery damage compared to high blood pressure with normal pulse pressure.<sup>30</sup> Recent work suggests that a high pulse pressure is an important risk factor for heart disease. A meta-analysis in 2000, which combined the results of several studies of 8,000 elderly patients in all, found that a 10 mm Hg increase in pulse pressure increased the risk of major cardiovascular complications and mortality by nearly 20%.<sup>31</sup>

A positive association between high hs-CRP level and high MAP was also found in the present study. Many other studies found the same relationship.<sup>32,33</sup>

In the present study, hs-CRP was positively related to LVM and LVMI, an echocardiographic marker of left ventricular hypertrophy (LVH). This result is compatible with other previous studies<sup>34</sup>, which found that patients with different involved target organ had different inflammatory degree, which hypertensive patients with LVH had the highest hs-CRP levels.

Finally, in the present study, hs-CRP was negatively related to vitamin D level. Although vitamin D deficiency involves mainly musculoskeletal system, growing evidence suggests that vitamin D affects the cardiovascular system also.<sup>7</sup> Recent clinical studies showed that low levels of vitamin D are associated with a higher prevalence of hypertension and LVH.<sup>35</sup> Elevated hs-CRP and vitamin D deficiency are associated with inflammatory changes that have been associated with cardiovascular events.<sup>36</sup>

#### V. CONCLUSIONS

Higher levels of hs-CRP were seen in hypertensive patients than normotensives. The higher hs-CRP levels were significantly correlated with higher grades of hypertension. Hs-CRP was positively correlated to lipid profile and inversely correlated to vitamin D. Increased levels of hs-CRP in hypertension implies a role of inflammation in hypertension. Hs-CRP estimation may be recommended in evaluation of all hypertensive patients.

*Conflicts of interest:*

The authors report no conflicts of interest

#### REFERENCES RÉFÉRENCES REFERENCIAS

1. Robert OB, Douglas LM, Douglas PZ, Peter L, editors. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Ninth Edition. USA: Saunders; 2011.
2. Ministry of Health/Iraq & World Health Organization. Chronic Non Communicable Diseases Risk Factors Survey in Iraq. 2006.
3. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. *Circulation* 2003; 108: 2993-9.

4. LiJian-jun. Inflammation in hypertension: primary evidence. *Chin Med J* 2005; 119: 1215-21.
5. Bautista LE, Atwood JE, O'Malley PG, Taylor AJ. Association between C-reactive protein and hypertension in healthy middle-aged men and women. *Coron Artery Dis* 2004; 15: 331-6.
6. Holick MF. Prevalence of vitamin D inadequacy and implication for health. *Mayo Clin Proc* 2006; 81: 355-73.
7. Li YU, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1, 25-dihydroxyvitamin D3 is a negative endocrine regular of the rennin-angiotensin system .*J Clin Invest* 2002; 110: 229-38.
8. Pauleto P, Rattazzi M. Inflammation and hypertension: the search for a link. *Nephrol Dial Transplant* 2006; 21: 850-53.
9. Corrado E, Novo S. Role of inflammation and infection in vascular disease. *Acta Chir. Belg.* 2005; 105 (6): 567-79.
10. "Normal results". C-reactive protein. Medline Plus. Retrieved 23 April 2015.
11. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Assessment of C-reactive protein in risk prediction for cardiovascular disease". *Annals of Internal Medicine* 2006; 145 (1): 35–42.
12. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults- the evidence report. *Obes Res* 1998; 6 suppl 2: 51-209.
13. Paul AJ, Suzanne O, Barry LC, William CC, Cheryl DH, Joel H, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014; 311(5): 507-520. doi:10.1001/jama.2013.284427.
14. lang RM, Bierig M, Devreux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Chamber Quantification Writing Group. Recommendations for Chamber Quantification: A report from the American Society of Echocardiography's) Group, Developed in conjunction with the European Association of Echocardiography, a branch of The European Society of Cardiology. *J Am Soc Echocardiogr* 2005; 18: 1440-63.
15. Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. *Hypertension*. 1987; 9: 1119– 26.
16. Okin PM, Devereux RB, Jer S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. *JAMA* 2004; 292: 2343-9.
17. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *Am J Clin Nutr* 2006; 84: 18-28.
18. Nader Rifai and G. Russell Warnick. Lipids, lipoproteins, apolipoproteins and other cardiovascular risk factors. Teitz. text book of clinical chemistry. 4<sup>th</sup> Edition. Section IV. Chapter 26. Pages 943-48.
19. Zheng L, Sun Z, Li J, et al. "Pulse pressure and mean arterial pressure in relation to ischemic stroke among patients with uncontrolled hypertension in rural areas of China". *Stroke*. 2008; 39 (7): 1932–7.
20. Ki Chul Sung, Jung YulSuh, Bum Soo Kim, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. *American Journal of Hypertension* 2003; 16: 429-33.
21. Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and risk of developing hypertension. *JAMA* 2003; 290(22): 2945-51.
22. Bautista LE, Vera LM, Arenas IA and Gamarra G. Independent association between inflammatory markers (C-reactive protein, IL-6 and TNF-@) and essential hypertension. *Journal of Human Hypertension* 2005; 19: 149-154.
23. Sridevi Devaraj, Dan yan xu, Ishwarlal Jilal. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells implications for the metabolic syndrome and atherothrombosis. *Circulation* 2003; 107: 398-404.
24. Chao-Hung Wang, Shu-Hong Li, Richard D. Weisel, Paul WM Fedak, Aaron S Dumont, Paul Szmilko, et al. C-reactive protein up regulates angiotensin type I receptors in vascular smooth muscle. *Circulation* 2003; 107: 1783-1790.
25. Rasouli M and Kiasari M. Interactions of serum hs-CRP with apoB, apoB/A1 ratio and some components of metabolic syndrome amplify the predictive values for coronary artery disease. *Clin Biochem* 2006; 39(10):971-77.
26. Giovanni de Simone, Richard B Devereux, Marcello Chinali et al .Risk factors for Arterial Hypertension in adults with initial optimal blood pressure: the Strong Heart Study. *Hypertension*. 2006; 47(2): 162-7.
27. Mariana de marco, Giovanni de Simone , Mary J Roman, et al. Cardiovascular and metabolic predictors of progression of prehypertension into hypertension: The Strong Heart Study. *Hypertension* 2009; 54: 974-80.
28. Abramson IL, Weintraub WS, Vaccariano V. Association between pulse pressure and C-reactive protein among apparently healthy vs adults. *Hypertension* 2002; 39: 197-202.
29. Kampus P, Muda P, Kals J, et al. The relationship between inflammation and arterial stiffness in patients with essential hypertension. *Int J Cardiol* 2006; 112(1): 46-51.

30. Vaccarino, V, Berger AK, Abramson J, et al. Pulse pressure and risk of cardiac events in the Systolic Hypertension in the Elderly (SHE) program. *American Journal of Cardiology*, 2001 Nov 1; 88(9): 980-6.
31. Blacher J, Staessen JA, Girerd X, et al. "Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients". *Arch Intern Med*. 2000; 160 (8): 1085–9.
32. Chae CU, Lee RT, Rifai N, et al. Blood pressure and inflammation in apparently healthy men. *Hypertension* 2001; 38: 399-403.
33. Hensley K, Robinson KA, Gabbita SP, et al. Reactive oxygen species, cell signaling cell injury. *Free Radic Biol Med* 2000; 28: 1456-62.
34. Ding Y, wang J, Zhang P and Qu P. The relation of serum high-sensitive C-reactive protein to risk factors and target organ damage in hypertensive patients. *Heart* 2012; 98: 258-59.
35. Katarzyna S-S, Agnieszka O, Wiktoria W, Danuta C. Association of serum vitamin D with left ventricular hypertrophy in hypertensive patients. *JASH* 2014;8 (4); 65-66.
36. Lee JH, et al. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? *J Am Coll Cardiol* 2008; 52: 1949-56.

**Table 1 :** Comparison of baseline, biochemical and echocardiographic characteristics between hypertensives and normotensive participants.

Variables	Group I Normotensive N=70		Group II and III hypertensive N=130		p
	Mean	SD	Mean	SD	
Age	49.9	9.3	52.24	9.15	0.49
BMI	26.77	6.8	27.60	7	0.98
SBP	118	8.8	157.26	7.39	<0.001
DBP	78	4.7	95.49	4.2	<0.001
PP	40	4.1	61.77	2.3	<0.001
MAP	91.3	5.6	116.04	4.1	<0.001
Cholesterol	145.1	29.3	200.83	19.5	<0.001
TG	99.75	32	180.29	19.3	<0.001
LDL	71.52	17.9	113.56	20.1	<0.001
HDL	41.5	4.6	37.05	3.6	<0.001
EF	61.7	3.6	62.1	3.7	0.58
IVS	8.25	0.5	12.46	0.7	<0.001
PW	7.86	0.3	11.86	0.6	<0.001
Left atrium	25.12	1.25	33.17	2.1	<0.001
LVM	102	9.18	223.79	15.6	<0.001
LVMi	60.66	5.3	121.14	7.5	<0.001
RWT	0.38	0.01	0.50	0.03	<0.001
Vit D	17.3	7.4	7.61	5.6	<0.001
Hs-CRP	0.74	0.8	2.75	1.5	<0.001



**Table 2 :** Comparison of baseline, biochemical and echocardiographic characteristics between two hypertensive groups.

Variables	Hypertensive group (II and III) N=130				p
	Stage I Group II (n=67)		Stage II Group III (n=63)		
	Mean	SD	Mean	SD	
Age	51.74	8.4	52.75	9.9	0.89
BMI	27.40	9	27.80	5	0.57
SBP	142.92	8.29	171.6	6.5	<0.001
DBP	90.22	2.8	100.75	5.6	<0.001
Cholesterol	199.44	20.5	202.22	18.6	0.91
TG	179.78	19.1	180.8	29.5	0.87
LDL	111.52	19.2	115.61	21.1	0.74
HDL	36.6	1.8	37.5	6.1	0.8
PP	52.7	3.5	70.85	1.1	<0.001
MAP	107.2	3	124	5.3	<0.001
EF	62.4	3.5	61.8	3.9	0.85
IVS	11.65	0.6	13.28	0.9	<0.001
PW	11.07	0.5	12.66	0.7	<0.001
Left atrium	32.20	2	34.15	2.2	0.066
LVM	203.89	11.2	242.69	20.4	<0.001
LVMi	111.35	6.1	130.93	9.4	<0.001
RWT	0.47	0.02	0.54	0.04	0.001
Vit D	8.32	7.22	6.9	6.5	0.5
Hs-CRP	1.83	1.1	3.67	2.1	<0.001

**Table 3 :** Correlation of hs-CRP with serum lipid profile and other variables in hypertensive patients.

Variables	r value	P value
SBP	0.75	<0.001
DBP	0.68	<0.001
PP	0.7	<0.001
MAP	0.72	<0.001
Cholesterol	0.63	<0.001
TG	0.32	0.001
LDL	0.6	<0.001
HDL	-0.35	0.001
LVM	0.58	<0.001
LVMi	0.58	<0.001
Vit D	-0.32	0.044



GLOBAL JOURNAL OF MEDICAL RESEARCH: B  
PHARMA, DRUG DISCOVERY, TOXICOLOGY & MEDICINE  
Volume 16 Issue 3 Version 1.0 Year 2016  
Type: Double Blind Peer Reviewed International Research Journal  
Publisher: Global Journals Inc. (USA)  
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Endocrine Disruptors in Endometriosis

By Mariana Antunes Ribeiro & Wellerson Rodrigo Scarano

*Sao Paulo State University*

**Abstract-** Endometriosis is an estrogen-dependent disease, which involves the growth of endometrial tissue outside the uterine cavity, commonly in the pelvic region. The etiology of the disease is unclear, but multiple factors may contribute to its prognosis. Toxicological studies indicate that many chemicals are able to interfere with endocrine homeostasis, called endocrine disrupting chemicals (EDC) like Bisphenol A, Phtalate, Polychlorinated Biphenyls and Dioxins. As well documented, endometriosis is an estrogen-dependent disease; therefore, environmental toxicants that either mimic estrogen or enhance estrogenic exposure in the endometrium are thought to increase the risk of endometriosis. The purpose of this mini-review is to provide an overview of epidemiological studies, which have evaluated the relationship between endometriosis and exposure to endocrine disruptors.

**Keywords:** *endometriosis, endocrine disruptors, infertility, bisphenol-A, phthalate, PCBs, TCDD.*

**GJMR-B Classification :** *NLMC Code: WP 390*



*Strictly as per the compliance and regulations of:*



# Endocrine Disruptors in Endometriosis

Mariana Antunes Ribeiro <sup>α</sup> & Wellerson Rodrigo Scarano <sup>ο</sup>

**Abstract-** Endometriosis is an estrogen-dependent disease, which involves the growth of endometrial tissue outside the uterine cavity, commonly in the pelvic region. The etiology of the disease is unclear, but multiple factors may contribute to its prognosis. Toxicological studies indicate that many chemicals are able to interfere with endocrine homeostasis, called endocrine disrupting chemicals (EDC) like Bisphenol A, Phtalate, Polychlorinated Biphenyls and Dioxins. As well documented, endometriosis is an estrogen-dependent disease; therefore, environmental toxicants that either mimic estrogen or enhance estrogenic exposure in the endometrium are thought to increase the risk of endometriosis. The purpose of this mini-review is to provide an overview of epidemiological studies, which have evaluated the relationship between endometriosis and exposure to endocrine disruptors.

**Keywords:** endometriosis, endocrine disruptors, infertility, bisphenol-A, phthalate, PCBs, TCDD.

## I. ENDOMETRIOSIS

Endometriosis is an estrogen-dependent disease defined as the growth of endometrial glands and stroma at extra-uterine sites. Reports on the incidence of endometriosis vary widely, from approximately 10% of reproductive-aged women (Barbieri 1990) up to 30% of women with chronic pelvic pain (Howard 1993). These reports may underestimate the true prevalence of this disease, which may approach 45% of women in their reproductive years (Rawson 1991). Although retrograde menstruation occurs in 70-80% of women of reproductive age, not all develop endometriosis (Halme et al. 1984). Therefore, other factors must play a role in the pathogenesis of endometriosis, like genetic background, malfunctioning inflammatory/immunological mechanisms and potentially environmental factors (Bischoff & Leigh 2004).

Endometriosis is intimately associated with steroid metabolism and associated pathways, corresponding to the dominant roles estrogen receptors (ESRs) and progesterone receptors (PGRs) play in uterine biology. Both human and animal model studies show endometriosis is estrogen (E2) dependent and is regulated through the ESRs alpha and beta (*ESR1* and *ESR2*) (Burns et al. 2012; Han et al. 2015; Zhao et al. 2015). Toxicological studies indicate that many chemicals are able to interfere with endocrine

homeostasis, called endocrine disrupting chemicals (EDC), may directly or indirectly impair female reproduction (Mantovani 2006). The definition of endocrine disruptor by European Union is an exogenous substance able to mime the hormones that can interfere with the production, release, transportation, metabolism, link, action or elimination of natural hormones, which are responsible of maintenance of homeostasis and regulation on development processes (Caserta et al. 2008). The main targets EDC are bisphenol A (BPA), di-(2-ethylhexyl) phthalate (DEHP), mono-ethyl-hexyl phthalate (MEHP) and polyhalogenated aromatic hydrocarbons that consists of dioxins, mainly, 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD) and polychlorinated biphenyls (PCB). Recently, they have gained special attention as emerged chemicals because of their persistence in the environment, potential for bioaccumulation and toxicity. Nuclear receptors pathways are the main cellular targets of the EDC under study, thus they are considered meaningful biomarkers of effective dose. The panel of nuclear receptors includes estrogen receptor alpha (*ERα*) and beta (*ERβ*), androgen receptor (AR) and aryl hydrocarbon receptor (AhR), it of these act in different pathways (Caserta et al. 2013).

As well documented, endometriosis is an estrogen-dependent disease; therefore, environmental toxicants that either mimic estrogen or enhance estrogenic exposure in the endometrium are thought to increase the risk of endometriosis. Therefore, this article aims to review the main endocrine disruptors that may be involved with endometriosis.

## II. BISPHENOL A (BPA)

BPA is a compound used in the production of polycarbonate plastics and epoxy resins. Given its similarity to endogenous estrogen, BPA has the ability to interact with estrogen receptors and stimulate estrogen production and also alter gonadotrophin hormone secretion (Buck Louis et al. 2013). Cobellis and co-workers correlated BPA and endometriosis (Cobellis et al. 2009). In this study, they found detectable BPA serum levels in more than half of patients with endometriosis, whereas it was absent in women without the disease. This data is still controversial once other studies could not observe a relation between BPA and endometriosis (Buck Louis et al. 2013; Itoh et al. 2007). More studies should be performed once it was reported that BPA causes subfertility in male rats that neonatally exposed to 2.4 μg of the compound per day for five

*Author α:* Department of Morphology, Institute of Biosciences of Botucatu, Sao Paulo State University – UNESP, Botucatu, SP, Brazil.

*Author ο:* PhD, Department of Morphology, Institute of Biosciences of Botucatu, São Paulo State University – UNESP, Rua Professor Doutor Antonio Celso Wagner Zanin s/nº, Distrito de Rubião Júnior, Botucatu - SP, Brazil. e-mail: scarano@ibb.unesp.br

days, by subcutaneous injection. This subfertility is manifested as embryo resorption, also known as post-implantation loss. In these resorbed embryos, the expression levels of three types of DNA methyltransferases involved in CpG methylation were significantly decreased compared to viable embryos of neonatally BPA exposed males or control embryos. The authors suggested that BPA might have altered the epigenome. As suggested by Guo (2009), there is accumulating evidence supporting a concept that endometriosis is an epigenetic disease, therefore further studies should be performed to demonstrate the correlation between the epigenetics changes and BPA in endometriosis.

### III. PHTHALATES

Phthalates are chemicals used in numerous industrial and consumer products and also exhibit endocrine disruptive properties or to mimic or alter endogenous hormone activity. Adult human exposure to phthalates is primarily through ingestion of contaminated food from food processing machines and packaging materials and dermal application of personal care and cosmetic products. Exposure is also possible through inhalation of indoor air contaminated from building materials, and parenteral exposure through medical equipment such as IV tubing and blood bags (Upson et al. 2013). Di-(2-ethylhexyl) phthalate (DEHP) is the most commonly used chemical additive to provide flexibility to polyvinylchloride and in humans, it is likely that the stomach acid lipases hydrolyze DEHP into mono-(2-ethylhexyl) phthalate (MEHP)(Albert & Jégou 2013). This compound is metabolized quickly and excreted in urine without evidence of accumulation within the body. Phthalates produce antiandrogenic effects largely through the reduction in testosterone production and, possibly, reduced estrogen production at high doses (Buck Louis et al. 2013). Results of investigations into the pathophysiology of endometriosis have suggested that disease onset and progression involve steroid-related mechanisms, including hormone-related changes of the endometrium and peritoneal cavity, excess estrogen production by ectopic endometriotic lesions, and alterations in ovarian steroidogenesis. Thus, it is plausible that endocrine-disrupting chemicals such as phthalates may affect endometriosis risk(Ulukus et al. 2006).

The in utero and neonatal exposure to low doses of bisphenol A (BPA) and/or phthalates (DEHP/MEHP and BBP/DBP/MBP) may cause DNA hypermethylation/hypomethylation at CpG islands near gene promoter regions, histone modifications (acetylation, methylation, phosphorylation, ubiquitylation, sumoylation and ADP ribosylation), and expression of non-coding RNAs, including micro RNAs. These epigenetic marks can induce up/down alterations

in gene expression that may persist throughout a lifetime (Singh & Li 2012).

### IV. PCBS AND TCDD

The main group of environmental pollutants that have been proposed to play a role in the pathogenesis of endometriosis includes polyhalogenated aromatic hydrocarbons, a class of widespread environmental contaminants consisting of polychlorinated dibenzo-*p*-dioxins (PCDD), dibenzofurans and 12 polychlorinated biphenyls (PCB) (Schechter et al. 2006).

Dioxins are byproducts of industrial processes such as bleaching of paper pulp and the manufacture of certain pesticides and incineration of plastic and medical waste (Foster et al. 2010). Dioxins are lipophilic substances that resist biological and environmental degradation, remaining in the environment. Studies in animals have shown that 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) is considered the environmental contaminant, within dioxin group, with the greatest toxicity and thus is also significant to human health (Schechter et al. 2006).

Seventy-five dioxin congeners and 135 furan congeners comprise the complex mixture of dioxins, 7:10 congeners which are respectively capable of binding to and activating the aryl hydrocarbon receptor (AhR) (Van den Berg et al. 2006). This binding induces the proliferation, differentiation and apoptosis, although the mechanism for this stimulation is not completely understood (Kogevinas 2001). Of the 209 congeners of polychlorinated biphenyls (PCBs), twelve have the potential to activate the AhR (Van den Berg et al. 2006). In normal physiological conditions, AhR resides in an inactive state in the cytoplasm. After association with TCDD, the AhR is activated by a change in conformation and translocates to the nucleus where it forms a heterodimer with ARNT (Aryl hydrocarbon receptor nuclear translocator). The heterodimer binds to the XRE (Xenobiotic Response Element) and alters the expression of genes controlled by the enhancer XRES. XRES, with the conserved sequences " GCGTG " are found in the promoter regions of various genes involved in the metabolism of xenobiotics, including CYP1A1 (Cytochrome P450 Family, subfamily a polypeptide 1a - 1), CYP1A2 (Cytochrome P450 Family, 1, subfamily a polypeptide -2) CYP1B1 (Cytochrome P450 family, subfamily B, polypeptide 1 -1) and NAD(P)H quinone Oxidoreductase (Mimura & Fujii-Kuriyama 2003). In addition to the expression of various genes to CYP connection with TCDD because several toxicological effects such as teratogenesis, tumor promotion and immunosuppression (Shimizu et al. 2000).

Furthermore, it is reported that, in somatic cells, the gene expression of DNA methyltransferase 1 (Dnmt1) is controlled by the transcription factor Sp1 (Bigey et al. 2000) and the promoter region Dnmt 3B

also contains an Sp1 binding site (Ishida et al. 2003). The Sp1 is important for a number of physiological processes, including angiogenesis, cell cycle progression, inflammation and senescence (Chang & Hung 2012). Taking into account the involvement of Sp1 with DNMTs, the change of the activity of Sp1 may affect the level of expression of DNA methyltransferases and their activity. Lee et al (Lee et al. 2011) showed that exposure to TCDD causes Sp1 phosphorylation. Based on this evidence, the phosphorylated Sp1 would bind to receptors of DNMTs, thereby increasing its activity. Thus, changes in methylation status in the promoter region of some genes can cause alterations in gene expression and consequently contribute to endometriosis development.

Dioxins have also been postulated to stimulate the development of endometriosis via their immunosuppressive effects and their interference with the estrogen signaling pathway. The immunosuppressive effect of high doses of dioxins is well documented (Oh et al. 2005). Firstly, dioxin exposure may lead to inhibition of leukocyte phagocytic function, which is possibly important in the prevention of endometriosis by the elimination of menstrual debris (Levin et al. 2005). Additionally, dioxins can decrease immunological memory induce apoptosis in both T cells and B cells, inhibit T-lymphocyte function and decrease natural killer cell activity in plasma and peritoneal fluid (Puebla-Osorio et al. 2004; Ahmed et al. 2005). Furthermore, dioxin may stimulate the activity of peritoneal fluid macrophages and their local production of pro-angiogenic factors, cytokines (e.g. interleukin-1) and growth factors. The combined effect of immune dysfunction and peritoneal inflammation could favor the development of endometriosis. Furthermore, cellular changes or genetic predisposition may predestine an individual to the immunological modulation caused by dioxin exposure (Simsa et al. 2010).

Local estrogen production can be increased following dioxin exposure and facilitate development of endometriotic lesions by elevating mRNA expression of aromatase, the key catalytic enzyme in estrogen synthesis (Attar & Bulun 2006). Dioxins and PCB are known to interfere with estrogen concentrations. Both agonistic and antagonistic effects have been ascribed to dioxins and PCB by direct interference with the estrogen receptor or by the interaction between the activated aryl hydrocarbon receptor (AHR)/aryl hydrocarbon receptor nuclear translocator heterodimer and the estrogen receptor  $\alpha$  and  $\beta$ , leading to estrogen-dependent gene activation (Mimura & Fujii-Kuriyama 2003).

## V. CONCLUSION

Developing a better understanding the basic mechanisms that may allow environmental toxicants to promote endometriosis, will enable us to develop better

strategies to reduce the potential toxic impact of these compounds to the future generation.

## REFERENCES RÉFÉRENCES REFERENCIAS

- Ahmed, S. et al., 2005. Protein kinase C $\theta$  activity is involved in the 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced signal transduction pathway leading to apoptosis in L-MAT, a human lymphoblastic T-cell line. *The FEBS journal*, 272(4), pp. 903–15.
- Albert, O. & Jégou, B., 2013. A critical assessment of the endocrine susceptibility of the human testis to phthalates from fetal life to adulthood. *Human reproduction update*, 0(0), pp. 1–19.
- Attar, E. & Bulun, S.E., 2006. Aromatase and other steroidogenic genes in endometriosis: translational aspects. *Human reproduction update*, 12(1), pp. 49–56.
- Barbieri, R.L., 1990. Etiology and epidemiology of endometriosis. *American journal of obstetrics and gynecology*, 162(2), pp. 565–7.
- Van den Berg, M. et al., 2006. The 2005 World Health Organization reevaluation of human and Mammalian toxic equivalency factors for dioxins and dioxin-like compounds. *Toxicological sciences: an official journal of the Society of Toxicology*, 93(2), pp. 223–41.
- Bigey, P. et al., 2000. Transcriptional regulation of the human DNA Methyltransferase (dnmt1) gene. *Gene*, 242(1-2), pp. 407–18.
- Bischoff, F. & Leigh, J.O.E., 2004. Genetic Basis of Endometriosis. , 299, pp. 284–299.
- Buck Louis, G.M. et al., 2013. Bisphenol A and phthalates and endometriosis: the Endometriosis: Natural History, Diagnosis and Outcomes Study. *Fertility and sterility*, 100(1), pp.162–9. e1–2.
- Burns, K.A. et al., 2012. Role of estrogen receptor signaling required for endometriosis-like lesion establishment in a mouse model. *Endocrinology*, 153(8), pp. 3960–71.
- Caserta, D. et al., 2008. Impact of endocrine disruptor chemicals in gynaecology. *Human reproduction update*, 14(1), pp. 59–72.
- Caserta, D. et al., 2013. The influence of endocrine disruptors in a selected population of infertile women. *Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology*, 29(5), pp. 444–7.
- Chang, W.-C. & Hung, J.-J., 2012. Functional role of post-translational modifications of Sp1 in tumorigenesis. *Journal of biomedical science*, 19, p.94.
- Cobellis, L. et al., 2009. Measurement of bisphenol A and bisphenol B levels in human blood sera from healthy and endometriotic women. *Biomedical chromatography: BMC*, 23(11), pp. 1186–90.
- Foster, W.G., Maharaj-Briceño, S. & Cyr, D.G., 2010. Dioxin-induced changes in epididymal sperm count



- and spermatogenesis. *Environmental health perspectives*, 118(4), pp. 458–64.
15. Guo, S.-W., 2009. Epigenetics of endometriosis. *Molecular human reproduction*, 15(10), pp.587–607.
  16. Halme, J. et al., 1984. Retrograde menstruation in healthy women and in patients with endometriosis. *Obstetrics and gynecology*, 64(2), pp. 151–4.
  17. Han, S.J. et al., 2015. Estrogen Receptor  $\beta$  Modulates Apoptosis Complexes and the Inflammasome to Drive the Pathogenesis of Endometriosis. *Cell*, 163(4), pp. 960–974.
  18. Howard, F.M., 1993. The role of laparoscopy in chronic pelvic pain: promise and pitfalls. *Obstetrical & gynecological survey*, 48(6), pp. 357–87.
  19. Ishida, C. et al., 2003. Genomic organization and promoter analysis of the Dnmt3b gene. *Gene*, 310, pp. 151–9.
  20. Itoh, H. et al., 2007. Urinary bisphenol-A concentration in infertile Japanese women and its association with endometriosis: A cross-sectional study. *Environmental health and preventive medicine*, 12(6), pp. 258–64.
  21. Kogevinas, M., Human health effects of dioxins: cancer, reproductive and endocrine system effects. *Human reproduction update*, 7(3), pp. 331–9.
  22. Lee, Y.C. et al., 2011. 2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced MUC5AC expression: aryl hydrocarbon receptor-independent/EGFR/ERK/p38-dependent SP1-based transcription. *American journal of respiratory cell and molecular biology*, 45(2), pp. 270–6.
  23. Levin, M. et al., 2005. Non-coplanar PCB-mediated modulation of human leukocyte phagocytosis: a new mechanism for immunotoxicity. *Journal of toxicology and environmental health. Part A*, 68(22), pp. 1977–93.
  24. Mantovani, A., 2006. Risk assessment of endocrine disruptors: the role of toxicological studies. *Annals of the New York Academy of Sciences*, 1076, pp. 239–52.
  25. Mimura, J. & Fujii-Kuriyama, Y., 2003. Functional role of AhR in the expression of toxic effects by TCDD. *Biochimica et biophysica acta*, 1619(3), pp. 263–8.
  26. Oh, E. et al., 2005. Evaluation of immuno- and reproductive toxicities and association between immunotoxicological and genotoxicological parameters in waste incineration workers. *Toxicology*, 210(1), pp. 65–80.
  27. Puebla-Osorio, N. et al., 2004. 2,3,7,8-Tetrachlorodibenzo-p-dioxin elicits aryl hydrocarbon receptor-mediated apoptosis in the avian DT40 pre-B-cell line through activation of caspases 9 and 3. *Comparative biochemistry and physiology. Toxicology & pharmacology: CBP*, 138(4), pp. 461–8.
  28. Rawson, J.M., 1991. Prevalence of endometriosis in asymptomatic women. *The Journal of reproductive medicine*, 36(7), pp. 513–5.
  29. Schecter, A. et al., 2006. Dioxins: an overview. *Environmental research*, 101(3), pp. 419–28.
  30. Shimizu, Y. et al., 2000. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. *Proceedings of the National Academy of Sciences of the United States of America*, 97(2), pp. 779–82.
  31. Simsa, P. et al., 2010. Increased exposure to dioxin-like compounds is associated with endometriosis in a case – control study in women., pp. 681–688.
  32. Singh, S. & Li, S.S.-L., 2012. Epigenetic effects of environmental chemicals bisphenol a and phthalates. *International journal of molecular sciences*, 13(8), pp. 10143–53.
  33. Ulukus, M., Cakmak, H. & Arici, A., 2006. The role of endometrium in endometriosis. *Journal of the Society for Gynecologic Investigation*, 13(7), pp. 467–76.
  34. Upson, K. et al., 2013. Phthalates and risk of endometriosis. *Environmental research*, pp.1–7.
  35. Zhao, Y. et al., 2015. Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis. *Science translational medicine*, 7(271), p. 271ra9.



GLOBAL JOURNAL OF MEDICAL RESEARCH: B  
PHARMA, DRUG DISCOVERY, TOXICOLOGY & MEDICINE  
Volume 16 Issue 3 Version 1.0 Year 2016  
Type: Double Blind Peer Reviewed International Research Journal  
Publisher: Global Journals Inc. (USA)  
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Prevalence of Health Related Disability among Community Dwelling Urban Elderly from Middle Socio-Economic Strata in Serampore

By Partha Talukdar

*Serampore College*

**Abstract-** The present study has been conducted in Serampore, West Bengal. The health of geriatric population is a present as well as future concern. This poses mounting pressures on various socio-economic fronts of the state, including pension outlays, health care expenditures, saving levels etc. This makes it necessary to look into the various aspects of their problems: Health, social rejection, economic, psychological and other allied aspects. In the traditional joint families, infirmities were taken care of by the individuals, immediate circle of relations and family members. Older people enjoyed a sense of honour and authority and had the responsibility in decision-making. However, in recent times, as a result of changing circumstances due to demographic transition, rapid pace of industrialization and urbanization, disintegration of joint family structures into unitary ones, the older people become more vulnerable to physical disabilities as a result of different morbidities and poor health seeking behaviour. This study will prove to be useful for the planners and policy makers in Government and private organizations and will help in enhancing the understanding of the problems of elderly people in the state.

**Keywords:** *morbidity, elderly population, ageing, physical disabilities.*

**GJMR-B Classification :** *NLMC Code: W 84*



*Strictly as per the compliance and regulations of:*



© 2016. Partha Talukdar. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

# Prevalence of Health Related Disability among Community Dwelling Urban Elderly from Middle Socio-Economic Strata in Serampore

Partha Talukdar

**Abstract-** The present study has been conducted in Serampore, West Bengal. The health of geriatric population is a present as well as future concern. This poses mounting pressures on various socio-economic fronts of the state, including pension outlays, health care expenditures, saving levels etc. This makes it necessary to look into the various aspects of their problems: Health, social rejection, economic, psychological and other allied aspects. In the traditional joint families, infirmities were taken care of by the individuals, immediate circle of relations and family members. Older people enjoyed a sense of honour and authority and had the responsibility in decision-making. However, in recent times, as a result of changing circumstances due to demographic transition, rapid pace of industrialization and urbanization, disintegration of joint family structures into unitary ones, the older people become more vulnerable to physical disabilities as a result of different morbidities and poor health seeking behaviour. This study will prove to be useful for the planners and policy makers in Government and private organizations and will help in enhancing the understanding of the problems of elderly people in the state.

**Keywords:** morbidity, elderly population, ageing, physical disabilities.

## I. INTRODUCTION

The phenomenon of population ageing is becoming a major concern for the policy makers all over the world during the last two decades. Ageing of population is affected due to downward trends in fertility and mortality i.e. due to low birth rates with long life expectancies. Life expectancy at birth is projected to continue to rise in the coming years all over the world. The aged population has specific health problems that are basically different from those of adults or young persons. Most diseases in the aged are chronic in nature-cardiovascular, arthritis, stroke, cataract, deafness, chronic infections, cancer. Disease process is usually multiple. Availability and utilization of health services is an important determinant of the health status of population. The needs for health services tend to vary directly with the age of the individuals. The older the one gets, the more health care he needs. Although the aged people face multiple health problems, even then, they do not consider seeking medical aid and as a result, many conditions remain unreported and untreated till

**Author:** Assistant Professor, Department of Botany, Serampore College, West Bengal, India. e-mail: parthat.bot@seramporecollege.org

they become complicated. This emphasizes the need for strengthening of health care system for elderly population. According to Paul Wallace, all individuals should be prepared to face later years in life within their own limitation gloriously. Chhattisgarh is moving fast towards an 'aged society', with the aged population constituting 7.2 percent (India 8 percent) and in another 10 years, percentage of elderly is projected to be 10 percent. Though a large number of studies on various factors influencing the aged are available in western countries, not much data have been generated as applicable to the Indian scenario. Urban areas are expected to grow at higher rate as compared to non-urban. Consistent with these changes; there were health institutions both demographically and epidemiologically, hence associated with the changes in prevalence of chronic illnesses.

## II. MATERIAL AND METHODS

Serampore is an important city of Hooghly district, state of West Bengal, India. At the time of 2011 census, the population within the Municipal area of Serampore was 181,842. Study was conducted in randomly selected 32 areas distributed in Serampore city including Urban and Slum areas. List of zones and wards including Slum and Urban areas were obtained from Municipality of Serampore. From eight zones of Serampore city by simple random technique, four zones were selected. Out of the four zones, four wards were selected by simple random technique. From each ward, one slum area and one urban area were included in the study using simple random technique. A total of 32 areas were included in this study. Door to door survey was conducted. From each area, 20 elderly were included in study.

**Sampling method:** Multi stage simple random sampling technique.

**Sample size:** 640

Sample size was calculated by using statistical formula,  $n = Z^2 I-a/2 P (I-P)/d$

P = Morbidity Problems (50%),

d = Absolute Precision (4%), Confidence level = 95%

As there was no baseline study in Serampore, therefore it was not possible to estimate 'P', so a figure

of 0.5(50%) was used. This is the 'safest' choice for the population proportion, since the sample size required is largest when P = 0.5(50%) [128].

A total of 600 figures come using statistical formula. For making uniformity, 20 subjects from each of 32 areas were selected that comes 640. Therefore, a total 640 subjects were included in the study.

### III. OBJECTIVES OF THE STUDY

- 1) To study morbidity pattern in elderly population of Serampore city.
- 2) To determine the pattern of morbidity in elderly population of Serampore city.
- 3) To study the health-care seeking behaviour of elderly population.
- 4) To make suitable recommendations on the basis of the study.

### IV. OBSERVATIONS AND DISCUSSION

Table 1 : Sex wise distribution of level of cognition among studied elderly

Level of cognition	Male		Female		Total	
	No	%	No	%	No	%
Normal	89	47.34	99	52.65	188	29.37
Some degree of mental confusion	155	37.25	261	62.74	416	65
Severe confusion	23	63.88	13	36.11	36	5.62
Total	267	41.71	373	58.28	640	100

Chi-square = 13.123 (df = 2, p < 0.001)

Above table shows statistically significant relation between level of cognition and sex of study population. Cognition was normal in 29.37% elderly whereas 65% had some degree of mental confusion, 5.62% had severe confusion. Severe confusion was more among males(63.88%) than females (36.11%).In another

study by Srinivasan Krishnamachari et al (2010), reported that cognitive impairment was shown to be positively associated with disability and was independent of age, gender and co-morbid medical condition. Present study shows sex differentiation among cognitive impairment. More males were severely confused than females.

Table 2 : Association of Morbidity with Socio-economic status in elderly population

SES	Morbid		Healthy		Total	
	No	%	No	%	No	%
Class I	68	(94.44)	4	(5.55)	72	11.25
Class II	158	(91.32)	15	(8.67)	173	27.03
Class III	120	(95.23)	6	(4.76)	126	19.68
Class IV	229	(98.28)	4	(1.71)	233	36.40
Class V	35	(97.22)	1	(2.77)	36	5.62
Total	610	(95.31)	30	(4.68)	640	100

Chi-square = 11.162 (df = 4, p = 0.024)

Above Table-2 shows that there is statistically significant association between morbidity and socio-economic status. Maximum morbidity(37.54%) was observed in Class IV Socioeconomic status(98.28%) followed by Class V (97.22%), Class III (95.23%), Class I

(94.44%) and Class II (91.32%).In present study, maximum morbidity was in Class IV and V Socio-economic group and all belonged to slum areas and were vulnerable group related to both environmental factors and literacy status.

Table 3 : Age and sex wise distribution of illnesses in elderly

Age groups in yrs	No examined	Persons ill	Number of illness		Total illnesses	Mean no of illnesses
			Male	Female		
60-74	523	495(94.64)	652	1303	1955	3.94
75-84	114	112(98.24)	261	226	487	4.34
>85	03	3(100)	0	19	19	6.33
Total	640	610(95.31)	913	1548	2461	4.03

Above Table-3 shows that, out of 640 elderly included in the study, 610 (95.31%) were found to have one or more illnesses at the time of examination. There was 2461 illnesses in 610 persons, 913 in males and 1548 in females. Mean number of illness was 4.03. In males, 3.78 whereas in females, mean number of illness was 4.19. There was positive association between mean number of illness and advancement of age. Mean illness for young old was 3.94, for old was 4.34 and for very old was 6.33.

Prevalence of illness was 100% among very old, 98.24% among old and 94.64% among young old. Similar findings were observed in another study done by M Jamal et al (1977), observed that 88.66% in their study were found to be ill; 86.67% males and 90.78% females. Illness was observed more frequently in older age group; 79.36% in young old to 100% in very old. Raj and Prasad (1970) observed that the brunt of illnesses fell on the persons who were 80 years and over.

Table 4 : Age wise distribution of total illnesses in study area

Age group	Slum		Urban		Total	
	No	%	No	%	No	%
60-74	950	(75.15)	1005	(83.95)	1955	(79.43)
75-84	295	(23.33)	192	(16.04)	487	(19.78)
>85	19	(1.50)	0	0	19	(0.77)
Total	1264	(51.36)	1197	(48.63)	2461	(100)

Chi-square = 40.538 (df = 2, p < 0.0001)

Above Table-4 shows statistically significant relation between age and illness of slum and urban elderly. Overall total illness was more in young old (79.43%), followed by old (19.78%) and very old (0.77%); but the mean was increasing with advancement of age. In urban areas, 83.95% of illnesses lying in young old

whereas in slum areas, 75.15% illnesses were in young old. Young old in urban areas were more overweight and obese and physically less active, whereas young old in slum areas were more active and were heavy activity performer. In old and very old, illnesses were more in slum than urban dwellers.

Table 5 : Age sex wise distribution of spells of illness in morbid elderly (n=610)

Age groups in years	Persons ill		Spells of illnesses			
	Male	Female	Male	Mean Spells	Female	Mean Spells
60-74	176	319	773	4.39	1526	4.78
75-84	65	47	293	4.50	262	5.57
>85	0	3	0	0	22	7.33
Total	241	369	1066	4.42	1810	4.90

Chi-square = 83.484 (df = 2, p < 0.0001)

Above Table-5 shows statistically significant relation between mean of spells of illness and age. In both sexes, mean spell was increasing with

advancement of age. In males, mean was more (4.42) in comparison to females (4.90).

Table 6 : Distribution of elderly as per subjective perception of health status

Perceived Health status	Number of elderly	Percentage (%)
Well	174	27.18
Ill	466	72.81
Total	640	100

Table-6 shows that 72.81% population perceived themselves ill, whereas 27.18% perceived well.

Table 7 : Sex wise distribution of subjective perception of health status in elderly

Health status	Male	Female	Total
Well	85(31.85%)	89(23.86%)	174(27.18%)
Ill	182(68.16%)	284(76.13%)	466(72.81%)
Total	267	373	640(100%)

Chi-square = 4.999 (df = 1, p = 0.025).

Above table shows that 72.81% population perceived themselves ill. Out of the total female population, 76.13% and out of the total male population, 68.16% perceived themselves ill.

**Table 8 :** Age wise Health seeking practice of elderly (n=466)

Age group (years)	Treatment taken	Treatment not taken	Total
60-74	361(97.30%)	10(2.69%)	371
75-84	92(100%)	0	92
>85	3(100%)	0	3
Total	456(97.85%)	10(2.14%)	466

Chi-square 2.617 (df 2, p = 0.270).

Above table shows that 97.85% of the elderly were observed to be receiving treatment where as 2.14% were not receiving treatment. With advancement of age, health care seeking was increased from 97.30% in young old to 100% in very old.

**Table 9 :** Sex wise Health seeking practice of elderly (n=466)

Sex	Treatment taken	Treatment not taken	Total
Male	180(98.90%)	2(1.09%)	182
Female	276(97.18%)	8(2.81%)	284
Total	456(97.85%)	10(2.14%)	466

Chi-square 1.559 (df=1, p = 0.211).

Above table shows that, out of total 466 elderly who perceived themselves ill, 97.85% were taking treatment whereas 2.14% did not take any treatment. Among males who perceived themselves ill, 98.90% had taken treatment whereas among females 97.18% had taken treatment.

**Table 10 :** Health seeking as per agency of treatment in Urban and Slum elderly

Area	Government	Private	Quacks	Others	Total
Urban	72(29.26%)	127(51.62%)	38(15.44%)	9(3.65%)	246(53.94%)
Slum	55(26.19%)	35(16.66%)	82(39.04%)	38(18.09%)	210(46.05%)
Total	127(27.85%)	162(35.52%)	120(26.31%)	47(10.30%)	456(100%)

Chi-square = 86.24 (df = 3, p= 0.000).

Above Table-10 shows that, out of total 466 elderly who perceived themselves ill, 456 elderly were taking treatment. Out of 456 elderly who were taking treatment, 53.94% were residing in urban areas whereas 46.05% were residing in slum areas. Out of various agencies, maximum were utilizing private facility (35.52%) followed by Government agency (27.85%), quacks (26.31%) and 10.30% from other source. In urban elderly, maximum were utilizing private facility (51.62%), followed by Government (29.26%), quacks (15.44%) and others (3.65%). Among slum dwellers, maximum elderly went to quacks (39.04%) followed by Government facility (26.19%), others (18.09%) and private facility (16.66%). This may be due low socio-economic status of slum elderly and high socio-economic status among urban dwellers.

**Table 11 :** Distribution of reasons for not utilizing Government facility

Reasons	Persons	Percentage (%)
Health centre too far	16	4.86
Facility available but lack of faith	4	1.21
Long waiting time	147	44.68
Due to misconduct of staff	110	33.43
Others*	52	15.80
Total	329	100

\*Others included OPD time not suitable.

Present study shows that, out of total 456 elderly seeking treatment from different agencies, only 127 elderly were taking treatment from Government facility ; rest 329 were not utilizing Government facility. Above

table shows that most common reasons for not utilizing Government facility were long waiting time (44.68%), due to misconduct of staff (33.43%) and others. Others

included not suitable OPD time. The least common reasons were too far health centre (4.86%), lack of faith (1.21%).

**Table 12 :** Distribution of reasons for not utilizing Government facility in Urban and Slumelderly

Reasons	Urban		Slum		Total	
	No	%	No	%	No	%
Health centre too far	1	0.57	15	9.67	16	4.86
Facility available but lack of faith	3	1.72	1	0.64	4	1.21
Long waiting time	95	54.59	52	33.54	147	44.68
Due to misconduct of staff	23	13.21	87	56.12	110	33.43
Others*	52	29.88	0	0	52	15.80
Total	174	100	155	100	329	100

Chi-square = 114.34 (df= 4, p = 0.000)

Table-12 shows that total 329 elderly were not utilizing Government facility, out of which 174 belonged to urban areas and 155 belonged to slum areas. Most common reasons for not utilizing government facility were long waiting time in 44.68%, Misconduct of staff 33.43% and others 15.80%. Least common reasons were too far health centre (4.86%) and lack of faith

(1.21%). Common reasons for not utilizing Government facility among urban elderly were long waiting time in 54.59%, misconduct of staff 13.21%; whereas in slum elderly, misconduct of staff was the major reason in 56.12% for not seeking care from Government facility, followed by long waiting time (33.54%).

**Table 13 :** Health seeking as per system of medicine (n=456)

Age group (years)	Allopathic	Ayurveda	Homeopathy	Others	Total
60-74	308(85.31)	14(3.87)	18(4.98)	21(5.81)	361
75-84	86(93.47)	1(1.08)	0	5(5.43)	92
>85	3(100)	0	0	0	3
Total	397(87.06)	15 (3.28)	18(3.94)	26(5.70)	456

Chi-square = 7.382 (df = 6, p = 0.286) Figure in parenthesis denote percentages.

Above table shows that majority of the elderly availed modern allopathic system of therapy (87.06%). Homeopathy was also used by a substantial percentage

of elderly (3.94%). Advancement of age had positive association with allopathic system of therapy from 85.31% in young old to 100% in very old age groups.

**Table 14 :** Distribution of reasons for not seeking health care (n=10)

Reasons for not seeking health care	Persons	Percentage
Financial reasons	1	10
Considered disease due to age	1	10
Nobody to take me to hospital	5	50
Health services too far	3	30
Total	10	100

Out of 466 who perceived themselves ill, only 10 did not take any treatment. Above table shows that 50% were not seeking health-care due to nobody was available to take them to hospital, 30% were not seeking health-care due to too far health services, where as 10% shows financial reasons and disease due to old age were observed in 10%.



Table-14 : Distribution of elderly spending on health as percent of per capita income in Urban and Slum areas

% of Per capita income	Urban		Slum		Total	
	No	%	No	%	No	%
<10%	161	50.94	155	49.05	316	62.94
10-20%	56	56	44	44	100	19.92
20-30%	29	80.55	7	19.44	36	7.17
>30%	0	0	4	100	4	0.79
Total	246	49.00	210	41.83	456	100

Chi-square = 16.258 (df = 3, p = 0.001)

Above table shows statistically significant relation between urban and slum elderly on health spending. Table-14 shows that, expenditure on health was more in urban than slum elderly. This is similar to trend at national and international level. Those who are more developed and economically more sound are

spending more on health than developing countries. In slum areas, maximum of their income is spent on food. In another study by Srinivasan Krishnamachari et al (2010), reported that majority of the elderly spent less than 10% of their monthly income on medication and health related issues.

Table 15 : Distribution of diseases of genitourinary system

Diseases	Male(n=241)	%	Female(n=369)	%	Total(n=610)	%
Urinary Incontinence	6	2.48	1	0.27	7	1.14
BPH	19	7.88	0	0	19	3.11
UTI	14	5.80	10	2.71	24	3.93
Stress Incontinence	0	0	1	0.27	1	0.16
Trichomonas vaginitis	0	0	3	0.81	3	0.49
Carcinoma Cervix	0	0	1	0.27	1	0.16
Prolapsed Uterus	0	0	2	0.54	2	0.32
Total	39	-	18	-	57	-

Note: Multiple disorders have been seen in many subjects.

The study shows, prevalence of Genitor urinary system disorders was 7.37%; among males prevalence was 12.03% whereas in females 4.33%. Above table shows, out of all disorders of Genitor- urinary system, common disorders were Urinary tract infection (UTI) (3.77%), Benign Prostatic Hypertrophy (BPH) (3.44%), Urinary Incontinence (1.14%). The least common condition was Trichomonas vaginitis (0.49%), Prolapsed Uterus (0.32%), Stress Incontinence (0.16%), and Carcinoma Cervix (0.16%). Among males, the commonest condition observed was Benign Prostatic Hypertrophy followed by UTI, whereas among females, Urinary Tract Infection was the commonest illness. In other study done by Shradha K et al (2012) reported prevalence of Genitourinary disorders as only 1.7%. The commonest condition was Renal calculi (1.4%), Urinary Incontinence (0.9%), Urinary frequency (0.9%) and Urinary Tract Infection (UTI) (0.9%). Renal Calculi and Urinary Incontinence was almost equally distributed in both genders, while Urinary frequency and UTI was reported by only female respondents. Present study was different from Shradha K et al (2012), UTI were distributed in both genders. P Ray Karmakar et al (2012), in their study showed that 9.8% elderly had Genito urinary system disorders. Male suffered more (10.3%) than females

(9.3%), which is comparable to 9.35% observed by Purohit and Sharma (1976). In present study almost similar feature has been reported. A study from Israel by Polliack and Bialik (1975) revealed very high prevalence (over 33.0%) of Benign Prostatic Hypertrophy, which might be due to older study population (65 years and above) and possibly better cooperation in conducting internal examination, on account of greater awareness and health consciousness. In the present study, the elderly population is 60 years and above thereby diluting the percentage of BPH cases found, as this is a disease more common in higher age groups. In present study, there was limitation for internal examination of female and male genital organ. Diagnosis was made on the basis of history, presenting symptoms and available medical records and medicines if possible.

## V. CONCLUSION

The present study is an endeavour to find out the morbidity pattern among elderly in Serampore city on a small scale of young growing state of West Bengal, along with the existing health practices and finally to suggest a pattern of health services suitable for the elderly population in the city. The study was conducted in 640 elderly subjects selected randomly from 32 areas



including urban and slum areas from 8 zones and 77 wards of Serampore city. Elderly persons in the age group, 60 years and above were 63635 (6.3% of total population in Serampore city), out of which only 640 persons (267 males and 373 females) were included in the study. Elderly females 373 (58.28%) out-numbered elderly males 267 (41.71%). Majority of the elderly persons (81.71%) belonged to "young old" age group. Bulk 40.15% of the elderly persons received education upto higher secondary. Graduates and above was only 15.78%, out of which 83.16% were in urban whereas 16.83% were from slum areas.

36.40% of the elderly population belonged to socio-economic Class IV, followed by Class II. A large proportion (84.07%) was living in joint families and 15.93% in nuclear family settings. Only 5.93% were living alone. 51.09% of the elderly were themselves heading the family with males predominating. A large proportion 42.03% of elderly population was unemployed. The principle occupation of the persons who were currently employed in some gainful occupation was agriculture/shop owner/clerical 11.25%, while 18.12% were professional including retired persons. A large proportion 48.28% was financially dependent on others. Only 14.84% were receiving old age pension. Out of total dependent, 66.66% were dependent on their children, 13.26% on grand children and 1.29% on spouse, 14.56% on others. A small proportion 33.59% was aware about various Government welfare schemes for the elderly. The geriatric population is a dependent population. Hence, health care delivery system should reorganize their timing other than routine schedule. Periodic comprehensive health check up, preferably twice a year must be carried out and primary health care delivery must be ensured to geriatric population.

## REFERENCES RÉFÉRENCES REFERENCIAS

1. Aggarwal Anupam. *A study of the morbidity status of geriatric population in the rural areas of Delhi*, New Delhi, India, 1992.
2. Campbell AJ, Reinken J, Allen BC. *Thyroid disease in the elderly in the community*. Age Ageing 1981; 10: 47-52.
3. Goel PK, Garg SK, Singh JV et al. *Unmet needs of the elderly in rural population of Meerut*. Indian J Community Med, 2003; 28: 165-6.
4. Goswami S et al. *Premature Birth: An Enigma for the Society?* European Journal of Medicine, Vol 6, No 4: pp 215-225, DOI-10.13187/ejm.2014.6.215.
5. Goswami S, Sahai M. *A Study of Psychosocial Risk Status and Knowledge of Reproductive Health in Adolescents in Serampore City*. European Journal of Medicine, 2015, Vol 9, Is 3: pp 139-149, DOI:10.13187/ejm.2015.9.139.
6. Hanger HC, Sainsbury R. *Screening the elderly-a Christchurch study*. The N Z Med J, 1990 Oct 10; 103 (899): 473-475.?
7. Krishnamachari Shrinivasan, Mario Vaz, Tinku Thomas. *Prevalence of health related disability among community dwelling urban elderly from middle socio-economic strata in Bengaluru, India*. Indian J Med Res 131, April 2010: p 515-521.
8. Lena A, Ashok K, Padma M. *Health and social problems of the elderly: A cross-sectional study in Udupi Taluk, Karnataka*. Indian Journal of Community Medicine, Vol. XXIX, No 1, Jan-Mar, 2004.
9. Lena A, Ashok K, Padma M. *Health and social problems of the elderly: A cross-sectional study in Udupi Taluk, Karnataka*. Indian Journal of Community Medicine, Vol.34, Issue 2, April 2009.
10. Longo et al. *Textbook of Harrison's Principles of Internal Medicine. 18th edition*. The McGraw Hill Companies, Inc. U.S. 2012, p 570.
11. Mittra et al. *A social study in the aged population of the urban health centre, Anambah, Lucknow*". Ind J.P. & S.M. 2: 139.
12. P Ray Karmakar, A Chattopadhyay. *A study on morbidity pattern and care seeking behaviour of elderly in rural area of West Bengal, India*. International Journal of Basic and Applied Medical Sciences ISSN; 2277-2103, 2012, Vol. 2 (3) September-December: p. 221-227.
13. Purohit CK and Sharma R. *A study of aged 60 years and above in social profile*. Ind J Geront, 1972; 4: 71-83.
14. Purohit CK, Sharma R. *A study of general health status of persons aged 60 years and above in R.H.T.C. area Naraila*. Ind J Med Res 1976, 64 (2): 202
15. Raj B.A. *Medico social study of aged persons in certain villages*. Ind Med Gaz 1971; 10 (9): 25-31.
16. Raj B, Prasad BG. *Health status of aged in India: A study in three villages*. Geriatrics 1970; 25: 142-158.
17. Sharma KL. *Leisure time activities of retired persons*. Ind J Geront 1969; 1 (1): 32-37.
18. Shraddha K, B Prashantha et al. *Study on morbidity pattern among elderly in urban population of Mysore, Karnataka, India*. International Journal of Medicine and Biomedical Research, Volume 1, Issue 3, September-December 2012; 1 (3): 215-223.
19. Sulakshna S Baliga, Praveen S Gopakumaran et al. *Treatment seeking behaviour and health-care expenditure incurred for hypertension among elderly in urban slums of Belgaum city*. National Journal of Community Medicine, Vol 4 (2), April-June 2013.
20. Swash Michael. *Hutchinson's Clinical Methods*, 20th edition ELBS with W.B. Saunders Company Ltd. 1995: p 387.
21. *The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure*, NIH Publication No. 04-5230, August 2004.
22. Vijayakumar S. *Population ageing in India*. Help Age India Research Development Journal Vol 5 (2) 1999.

# GLOBAL JOURNALS INC. (US) GUIDELINES HANDBOOK 2016

---

[WWW.GLOBALJOURNALS.ORG](http://WWW.GLOBALJOURNALS.ORG)

# FELLOWS

## FELLOW OF ASSOCIATION OF RESEARCH SOCIETY IN MEDICAL (FARSM)

Global Journals Incorporate (USA) is accredited by Open Association of Research Society (OARS), U.S.A and in turn, awards “FARSM” title to individuals. The 'FARSM' title is accorded to a selected professional after the approval of the Editor-in-Chief/Editorial Board Members/Dean.



- The “FARSM” is a dignified title which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., FARSS or William Walldroff, M.S., FARSM.

FARSM accrediting is an honor. It authenticates your research activities. After recognition as FARSM, you can add 'FARSM' title with your name as you use this recognition as additional suffix to your status. This will definitely enhance and add more value and repute to your name. You may use it on your professional Counseling Materials such as CV, Resume, and Visiting Card etc.

*The following benefits can be availed by you only for next three years from the date of certification:*



FARSM designated members are entitled to avail a 40% discount while publishing their research papers (of a single author) with Global Journals Incorporation (USA), if the same is accepted by Editorial Board/Peer Reviewers. If you are a main author or co-author in case of multiple authors, you will be entitled to avail discount of 10%.

Once FARSM title is accorded, the Fellow is authorized to organize a symposium/seminar/conference on behalf of Global Journal Incorporation (USA). The Fellow can also participate in conference/seminar/symposium organized by another institution as representative of Global Journal. In both the cases, it is mandatory for him to discuss with us and obtain our consent.



You may join as member of the Editorial Board of Global Journals Incorporation (USA) after successful completion of three years as Fellow and as Peer Reviewer. In addition, it is also desirable that you should organize seminar/symposium/conference at least once.

We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.





The FARSM can go through standards of OARS. You can also play vital role if you have any suggestions so that proper amendment can take place to improve the same for the benefit of entire research community.

As FARSM, you will be given a renowned, secure and free professional email address with 100 GB of space e.g. [johnhall@globaljournals.org](mailto:johnhall@globaljournals.org). This will include Webmail, Spam Assassin, Email Forwarders, Auto-Responders, Email Delivery Route tracing, etc.



The FARSM will be eligible for a free application of standardization of their researches. Standardization of research will be subject to acceptability within stipulated norms as the next step after publishing in a journal. We shall depute a team of specialized research professionals who will render their services for elevating your researches to next higher level, which is worldwide open standardization.

The FARSM member can apply for grading and certification of standards of their educational and Institutional Degrees to Open Association of Research, Society U.S.A. Once you are designated as FARSM, you may send us a scanned copy of all of your credentials. OARS will verify, grade and certify them. This will be based on your academic records, quality of research papers published by you, and some more criteria. After certification of all your credentials by OARS, they will be published on your Fellow Profile link on website <https://associationofresearch.org> which will be helpful to upgrade the dignity.



The FARSM members can avail the benefits of free research podcasting in Global Research Radio with their research documents. After publishing the work, (including published elsewhere worldwide with proper authorization) you can upload your research paper with your recorded voice or you can utilize chargeable services of our professional RJs to record your paper in their voice on request.

The FARSM member also entitled to get the benefits of free research podcasting of their research documents through video clips. We can also streamline your conference videos and display your slides/ online slides and online research video clips at reasonable charges, on request.





The FARSM is eligible to earn from sales proceeds of his/her researches/reference/review Books or literature, while publishing with Global Journals. The FARSS can decide whether he/she would like to publish his/her research in a closed manner. In this case, whenever readers purchase that individual research paper for reading, maximum 60% of its profit earned as royalty by Global Journals, will be credited to his/her bank account. The entire entitled amount will be credited to his/her bank account exceeding limit of minimum fixed balance. There is no minimum time limit for collection. The FARSM member can decide its price and we can help in making the right decision.

The FARSM member is eligible to join as a paid peer reviewer at Global Journals Incorporation (USA) and can get remuneration of 15% of author fees, taken from the author of a respective paper. After reviewing 5 or more papers you can request to transfer the amount to your bank account.



## MEMBER OF ASSOCIATION OF RESEARCH SOCIETY IN MEDICAL (MARSM)

The ' MARSM ' title is accorded to a selected professional after the approval of the Editor-in-Chief / Editorial Board Members/Dean.

The “MARSM” is a dignified ornament which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., MARSM or William Walldroff, M.S., MARSM.



MARSM accrediting is an honor. It authenticates your research activities. After becoming MARSM, you can add 'MARSM' title with your name as you use this recognition as additional suffix to your status. This will definitely enhance and add more value and repute to your name. You may use it on your professional Counseling Materials such as CV, Resume, Visiting Card and Name Plate etc.

*The following benefits can be availed by you only for next three years from the date of certification.*



MARSM designated members are entitled to avail a 25% discount while publishing their research papers (of a single author) in Global Journals Inc., if the same is accepted by our Editorial Board and Peer Reviewers. If you are a main author or co-author of a group of authors, you will get discount of 10%.

As MARSM, you will be given a renowned, secure and free professional email address with 30 GB of space e.g. [johnhall@globaljournals.org](mailto:johnhall@globaljournals.org). This will include Webmail, Spam Assassin, Email Forwarders, Auto-Responders, Email Delivery Route tracing, etc.





We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.

The MARSM member can apply for approval, grading and certification of standards of their educational and Institutional Degrees to Open Association of Research, Society U.S.A.



Once you are designated as MARSM, you may send us a scanned copy of all of your credentials. OARS will verify, grade and certify them. This will be based on your academic records, quality of research papers published by you, and some more criteria.

It is mandatory to read all terms and conditions carefully.



# AUXILIARY MEMBERSHIPS

## Institutional Fellow of Open Association of Research Society (USA) - OARS (USA)

Global Journals Incorporation (USA) is accredited by Open Association of Research Society, U.S.A (OARS) and in turn, affiliates research institutions as “Institutional Fellow of Open Association of Research Society” (IFOARS).



The “FARSC” is a dignified title which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., FARSC or William Walldroff, M.S., FARSC.

The IFOARS institution is entitled to form a Board comprised of one Chairperson and three to five board members preferably from different streams. The Board will be recognized as “Institutional Board of Open Association of Research Society”-(IBOARS).

*The Institute will be entitled to following benefits:*



The IBOARS can initially review research papers of their institute and recommend them to publish with respective journal of Global Journals. It can also review the papers of other institutions after obtaining our consent. The second review will be done by peer reviewer of Global Journals Incorporation (USA) The Board is at liberty to appoint a peer reviewer with the approval of chairperson after consulting us.

The author fees of such paper may be waived off up to 40%.

The Global Journals Incorporation (USA) at its discretion can also refer double blind peer reviewed paper at their end to the board for the verification and to get recommendation for final stage of acceptance of publication.



The IBOARS can organize symposium/seminar/conference in their country on behalf of Global Journals Incorporation (USA)-OARS (USA). The terms and conditions can be discussed separately.


The Board can also play vital role by exploring and giving valuable suggestions regarding the Standards of “Open Association of Research Society, U.S.A (OARS)” so that proper amendment can take place for the benefit of entire research community. We shall provide details of particular standard only on receipt of request from the Board.



The board members can also join us as Individual Fellow with 40% discount on total fees applicable to Individual Fellow. They will be entitled to avail all the benefits as declared. Please visit Individual Fellow-sub menu of GlobalJournals.org to have more relevant details.



We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.



After nomination of your institution as “Institutional Fellow” and constantly functioning successfully for one year, we can consider giving recognition to your institute to function as Regional/Zonal office on our behalf.

The board can also take up the additional allied activities for betterment after our consultation.

**The following entitlements are applicable to individual Fellows:**

Open Association of Research Society, U.S.A (OARS) By-laws states that an individual Fellow may use the designations as applicable, or the corresponding initials. The Credentials of individual Fellow and Associate designations signify that the individual has gained knowledge of the fundamental concepts. One is magnanimous and proficient in an expertise course covering the professional code of conduct, and follows recognized standards of practice.



Open Association of Research Society (US)/ Global Journals Incorporation (USA), as described in Corporate Statements, are educational, research publishing and professional membership organizations. Achieving our individual Fellow or Associate status is based mainly on meeting stated educational research requirements.

Disbursement of 40% Royalty earned through Global Journals : Researcher = 50%, Peer Reviewer = 37.50%, Institution = 12.50% E.g. Out of 40%, the 20% benefit should be passed on to researcher, 15 % benefit towards remuneration should be given to a reviewer and remaining 5% is to be retained by the institution.



We shall provide print version of 12 issues of any three journals [as per your requirement] out of our 38 journals worth \$ 2376 USD.

**Other:**

**The individual Fellow and Associate designations accredited by Open Association of Research Society (US) credentials signify guarantees following achievements:**

- The professional accredited with Fellow honor, is entitled to various benefits viz. name, fame, honor, regular flow of income, secured bright future, social status etc.





- In addition to above, if one is single author, then entitled to 40% discount on publishing research paper and can get 10% discount if one is co-author or main author among group of authors.
- The Fellow can organize symposium/seminar/conference on behalf of Global Journals Incorporation (USA) and he/she can also attend the same organized by other institutes on behalf of Global Journals.
- The Fellow can become member of Editorial Board Member after completing 3yrs.
- The Fellow can earn 60% of sales proceeds from the sale of reference/review books/literature/publishing of research paper.
- Fellow can also join as paid peer reviewer and earn 15% remuneration of author charges and can also get an opportunity to join as member of the Editorial Board of Global Journals Incorporation (USA)
- • This individual has learned the basic methods of applying those concepts and techniques to common challenging situations. This individual has further demonstrated an in-depth understanding of the application of suitable techniques to a particular area of research practice.

**Note :**

//

- In future, if the board feels the necessity to change any board member, the same can be done with the consent of the chairperson along with anyone board member without our approval.
- In case, the chairperson needs to be replaced then consent of 2/3rd board members are required and they are also required to jointly pass the resolution copy of which should be sent to us. In such case, it will be compulsory to obtain our approval before replacement.
- In case of “Difference of Opinion [if any]” among the Board members, our decision will be final and binding to everyone.

//



## PROCESS OF SUBMISSION OF RESEARCH PAPER

---

The Area or field of specialization may or may not be of any category as mentioned in 'Scope of Journal' menu of the GlobalJournals.org website. There are 37 Research Journal categorized with Six parental Journals GJCST, GJMR, GJRE, GJMBR, GJSFR, GJHSS. For Authors should prefer the mentioned categories. There are three widely used systems UDC, DDC and LCC. The details are available as 'Knowledge Abstract' at Home page. The major advantage of this coding is that, the research work will be exposed to and shared with all over the world as we are being abstracted and indexed worldwide.

The paper should be in proper format. The format can be downloaded from first page of 'Author Guideline' Menu. The Author is expected to follow the general rules as mentioned in this menu. The paper should be written in MS-Word Format (\*.DOC,\*.DOCX).

The Author can submit the paper either online or offline. The authors should prefer online submission.Online Submission: There are three ways to submit your paper:

**(A) (I) First, register yourself using top right corner of Home page then Login. If you are already registered, then login using your username and password.**

**(II) Choose corresponding Journal.**

**(III) Click 'Submit Manuscript'. Fill required information and Upload the paper.**

**(B) If you are using Internet Explorer, then Direct Submission through Homepage is also available.**

**(C) If these two are not convenient, and then email the paper directly to dean@globaljournals.org.**

Offline Submission: Author can send the typed form of paper by Post. However, online submission should be preferred.



# PREFERRED AUTHOR GUIDELINES

## MANUSCRIPT STYLE INSTRUCTION (Must be strictly followed)

Page Size: 8.27" X 11"

- Left Margin: 0.65
- Right Margin: 0.65
- Top Margin: 0.75
- Bottom Margin: 0.75
- Font type of all text should be Swis 721 Lt BT.
- Paper Title should be of Font Size 24 with one Column section.
- Author Name in Font Size of 11 with one column as of Title.
- Abstract Font size of 9 Bold, "Abstract" word in Italic Bold.
- Main Text: Font size 10 with justified two columns section
- Two Column with Equal Column with of 3.38 and Gaping of .2
- First Character must be three lines Drop capped.
- Paragraph before Spacing of 1 pt and After of 0 pt.
- Line Spacing of 1 pt
- Large Images must be in One Column
- Numbering of First Main Headings (Heading 1) must be in Roman Letters, Capital Letter, and Font Size of 10.
- Numbering of Second Main Headings (Heading 2) must be in Alphabets, Italic, and Font Size of 10.

**You can use your own standard format also.**

### Author Guidelines:

1. General,
2. Ethical Guidelines,
3. Submission of Manuscripts,
4. Manuscript's Category,
5. Structure and Format of Manuscript,
6. After Acceptance.

### 1. GENERAL

Before submitting your research paper, one is advised to go through the details as mentioned in following heads. It will be beneficial, while peer reviewer justify your paper for publication.

### Scope

The Global Journals Inc. (US) welcome the submission of original paper, review paper, survey article relevant to the all the streams of Philosophy and knowledge. The Global Journals Inc. (US) is parental platform for Global Journal of Computer Science and Technology, Researches in Engineering, Medical Research, Science Frontier Research, Human Social Science, Management, and Business organization. The choice of specific field can be done otherwise as following in Abstracting and Indexing Page on this Website. As the all Global

Journals Inc. (US) are being abstracted and indexed (in process) by most of the reputed organizations. Topics of only narrow interest will not be accepted unless they have wider potential or consequences.

## 2. ETHICAL GUIDELINES

Authors should follow the ethical guidelines as mentioned below for publication of research paper and research activities.

Papers are accepted on strict understanding that the material in whole or in part has not been, nor is being, considered for publication elsewhere. If the paper once accepted by Global Journals Inc. (US) and Editorial Board, will become the copyright of the Global Journals Inc. (US).

**Authorship: The authors and coauthors should have active contribution to conception design, analysis and interpretation of findings. They should critically review the contents and drafting of the paper. All should approve the final version of the paper before submission**

The Global Journals Inc. (US) follows the definition of authorship set up by the Global Academy of Research and Development. According to the Global Academy of R&D authorship, criteria must be based on:

- 1) Substantial contributions to conception and acquisition of data, analysis and interpretation of the findings.
- 2) Drafting the paper and revising it critically regarding important academic content.
- 3) Final approval of the version of the paper to be published.

All authors should have been credited according to their appropriate contribution in research activity and preparing paper. Contributors who do not match the criteria as authors may be mentioned under Acknowledgement.

Acknowledgements: Contributors to the research other than authors credited should be mentioned under acknowledgement. The specifications of the source of funding for the research if appropriate can be included. Suppliers of resources may be mentioned along with address.

**Appeal of Decision: The Editorial Board's decision on publication of the paper is final and cannot be appealed elsewhere.**

**Permissions: It is the author's responsibility to have prior permission if all or parts of earlier published illustrations are used in this paper.**

Please mention proper reference and appropriate acknowledgements wherever expected.

If all or parts of previously published illustrations are used, permission must be taken from the copyright holder concerned. It is the author's responsibility to take these in writing.

Approval for reproduction/modification of any information (including figures and tables) published elsewhere must be obtained by the authors/copyright holders before submission of the manuscript. Contributors (Authors) are responsible for any copyright fee involved.

## 3. SUBMISSION OF MANUSCRIPTS

Manuscripts should be uploaded via this online submission page. The online submission is most efficient method for submission of papers, as it enables rapid distribution of manuscripts and consequently speeds up the review procedure. It also enables authors to know the status of their own manuscripts by emailing us. Complete instructions for submitting a paper is available below.

Manuscript submission is a systematic procedure and little preparation is required beyond having all parts of your manuscript in a given format and a computer with an Internet connection and a Web browser. Full help and instructions are provided on-screen. As an author, you will be prompted for login and manuscript details as Field of Paper and then to upload your manuscript file(s) according to the instructions.



To avoid postal delays, all transaction is preferred by e-mail. A finished manuscript submission is confirmed by e-mail immediately and your paper enters the editorial process with no postal delays. When a conclusion is made about the publication of your paper by our Editorial Board, revisions can be submitted online with the same procedure, with an occasion to view and respond to all comments.

Complete support for both authors and co-author is provided.

#### 4. MANUSCRIPT'S CATEGORY

Based on potential and nature, the manuscript can be categorized under the following heads:

Original research paper: Such papers are reports of high-level significant original research work.

Review papers: These are concise, significant but helpful and decisive topics for young researchers.

Research articles: These are handled with small investigation and applications

Research letters: The letters are small and concise comments on previously published matters.

#### 5. STRUCTURE AND FORMAT OF MANUSCRIPT

The recommended size of original research paper is less than seven thousand words, review papers fewer than seven thousands words also. Preparation of research paper or how to write research paper, are major hurdle, while writing manuscript. The research articles and research letters should be fewer than three thousand words, the structure original research paper; sometime review paper should be as follows:

**Papers:** These are reports of significant research (typically less than 7000 words equivalent, including tables, figures, references), and comprise:

- (a) Title should be relevant and commensurate with the theme of the paper.
- (b) A brief Summary, "Abstract" (less than 150 words) containing the major results and conclusions.
- (c) Up to ten keywords, that precisely identifies the paper's subject, purpose, and focus.
- (d) An Introduction, giving necessary background excluding subheadings; objectives must be clearly declared.
- (e) Resources and techniques with sufficient complete experimental details (wherever possible by reference) to permit repetition; sources of information must be given and numerical methods must be specified by reference, unless non-standard.
- (f) Results should be presented concisely, by well-designed tables and/or figures; the same data may not be used in both; suitable statistical data should be given. All data must be obtained with attention to numerical detail in the planning stage. As reproduced design has been recognized to be important to experiments for a considerable time, the Editor has decided that any paper that appears not to have adequate numerical treatments of the data will be returned un-refereed;
- (g) Discussion should cover the implications and consequences, not just recapitulating the results; conclusions should be summarizing.
- (h) Brief Acknowledgements.
- (i) References in the proper form.

Authors should very cautiously consider the preparation of papers to ensure that they communicate efficiently. Papers are much more likely to be accepted, if they are cautiously designed and laid out, contain few or no errors, are summarizing, and be conventional to the approach and instructions. They will in addition, be published with much less delays than those that require much technical and editorial correction.



The Editorial Board reserves the right to make literary corrections and to make suggestions to improve brevity.

It is vital, that authors take care in submitting a manuscript that is written in simple language and adheres to published guidelines.

## Format

*Language: The language of publication is UK English. Authors, for whom English is a second language, must have their manuscript efficiently edited by an English-speaking person before submission to make sure that, the English is of high excellence. It is preferable, that manuscripts should be professionally edited.*

Standard Usage, Abbreviations, and Units: Spelling and hyphenation should be conventional to The Concise Oxford English Dictionary. Statistics and measurements should at all times be given in figures, e.g. 16 min, except for when the number begins a sentence. When the number does not refer to a unit of measurement it should be spelt in full unless, it is 160 or greater.

Abbreviations supposed to be used carefully. The abbreviated name or expression is supposed to be cited in full at first usage, followed by the conventional abbreviation in parentheses.

Metric SI units are supposed to generally be used excluding where they conflict with current practice or are confusing. For illustration, 1.4 l rather than  $1.4 \times 10^{-3} \text{ m}^3$ , or 4 mm somewhat than  $4 \times 10^{-3} \text{ m}$ . Chemical formula and solutions must identify the form used, e.g. anhydrous or hydrated, and the concentration must be in clearly defined units. Common species names should be followed by underlines at the first mention. For following use the generic name should be constricted to a single letter, if it is clear.

## Structure

All manuscripts submitted to Global Journals Inc. (US), ought to include:

Title: The title page must carry an instructive title that reflects the content, a running title (less than 45 characters together with spaces), names of the authors and co-authors, and the place(s) wherever the work was carried out. The full postal address in addition with the e-mail address of related author must be given. Up to eleven keywords or very brief phrases have to be given to help data retrieval, mining and indexing.

*Abstract, used in Original Papers and Reviews:*

### Optimizing Abstract for Search Engines

Many researchers searching for information online will use search engines such as Google, Yahoo or similar. By optimizing your paper for search engines, you will amplify the chance of someone finding it. This in turn will make it more likely to be viewed and/or cited in a further work. Global Journals Inc. (US) have compiled these guidelines to facilitate you to maximize the web-friendliness of the most public part of your paper.

### Key Words

A major linchpin in research work for the writing research paper is the keyword search, which one will employ to find both library and Internet resources.

One must be persistent and creative in using keywords. An effective keyword search requires a strategy and planning a list of possible keywords and phrases to try.

Search engines for most searches, use Boolean searching, which is somewhat different from Internet searches. The Boolean search uses "operators," words (and, or, not, and near) that enable you to expand or narrow your affords. Tips for research paper while preparing research paper are very helpful guideline of research paper.

Choice of key words is first tool of tips to write research paper. Research paper writing is an art. A few tips for deciding as strategically as possible about keyword search:



- One should start brainstorming lists of possible keywords before even begin searching. Think about the most important concepts related to research work. Ask, "What words would a source have to include to be truly valuable in research paper?" Then consider synonyms for the important words.
- It may take the discovery of only one relevant paper to let steer in the right keyword direction because in most databases, the keywords under which a research paper is abstracted are listed with the paper.
- One should avoid outdated words.

Keywords are the key that opens a door to research work sources. Keyword searching is an art in which researcher's skills are bound to improve with experience and time.

Numerical Methods: Numerical methods used should be clear and, where appropriate, supported by references.

*Acknowledgements: Please make these as concise as possible.*

#### References

References follow the Harvard scheme of referencing. References in the text should cite the authors' names followed by the time of their publication, unless there are three or more authors when simply the first author's name is quoted followed by et al. unpublished work has to only be cited where necessary, and only in the text. Copies of references in press in other journals have to be supplied with submitted typescripts. It is necessary that all citations and references be carefully checked before submission, as mistakes or omissions will cause delays.

References to information on the World Wide Web can be given, but only if the information is available without charge to readers on an official site. Wikipedia and Similar websites are not allowed where anyone can change the information. Authors will be asked to make available electronic copies of the cited information for inclusion on the Global Journals Inc. (US) homepage at the judgment of the Editorial Board.

The Editorial Board and Global Journals Inc. (US) recommend that, citation of online-published papers and other material should be done via a DOI (digital object identifier). If an author cites anything, which does not have a DOI, they run the risk of the cited material not being noticeable.

The Editorial Board and Global Journals Inc. (US) recommend the use of a tool such as Reference Manager for reference management and formatting.

#### Tables, Figures and Figure Legends

*Tables: Tables should be few in number, cautiously designed, uncrowned, and include only essential data. Each must have an Arabic number, e.g. Table 4, a self-explanatory caption and be on a separate sheet. Vertical lines should not be used.*

*Figures: Figures are supposed to be submitted as separate files. Always take in a citation in the text for each figure using Arabic numbers, e.g. Fig. 4. Artwork must be submitted online in electronic form by e-mailing them.*

#### Preparation of Electronic Figures for Publication

Even though low quality images are sufficient for review purposes, print publication requires high quality images to prevent the final product being blurred or fuzzy. Submit (or e-mail) EPS (line art) or TIFF (halftone/photographs) files only. MS PowerPoint and Word Graphics are unsuitable for printed pictures. Do not use pixel-oriented software. Scans (TIFF only) should have a resolution of at least 350 dpi (halftone) or 700 to 1100 dpi (line drawings) in relation to the imitation size. Please give the data for figures in black and white or submit a Color Work Agreement Form. EPS files must be saved with fonts embedded (and with a TIFF preview, if possible).

For scanned images, the scanning resolution (at final image size) ought to be as follows to ensure good reproduction: line art: >650 dpi; halftones (including gel photographs) : >350 dpi; figures containing both halftone and line images: >650 dpi.



Color Charges: It is the rule of the Global Journals Inc. (US) for authors to pay the full cost for the reproduction of their color artwork. Hence, please note that, if there is color artwork in your manuscript when it is accepted for publication, we would require you to complete and return a color work agreement form before your paper can be published.

*Figure Legends: Self-explanatory legends of all figures should be incorporated separately under the heading 'Legends to Figures'. In the full-text online edition of the journal, figure legends may possibly be truncated in abbreviated links to the full screen version. Therefore, the first 100 characters of any legend should notify the reader, about the key aspects of the figure.*

## **6. AFTER ACCEPTANCE**

Upon approval of a paper for publication, the manuscript will be forwarded to the dean, who is responsible for the publication of the Global Journals Inc. (US).

### **6.1 Proof Corrections**

The corresponding author will receive an e-mail alert containing a link to a website or will be attached. A working e-mail address must therefore be provided for the related author.

Acrobat Reader will be required in order to read this file. This software can be downloaded

(Free of charge) from the following website:

[www.adobe.com/products/acrobat/readstep2.html](http://www.adobe.com/products/acrobat/readstep2.html). This will facilitate the file to be opened, read on screen, and printed out in order for any corrections to be added. Further instructions will be sent with the proof.

Proofs must be returned to the dean at [dean@globaljournals.org](mailto:dean@globaljournals.org) within three days of receipt.

As changes to proofs are costly, we inquire that you only correct typesetting errors. All illustrations are retained by the publisher. Please note that the authors are responsible for all statements made in their work, including changes made by the copy editor.

### **6.2 Early View of Global Journals Inc. (US) (Publication Prior to Print)**

The Global Journals Inc. (US) are enclosed by our publishing's Early View service. Early View articles are complete full-text articles sent in advance of their publication. Early View articles are absolute and final. They have been completely reviewed, revised and edited for publication, and the authors' final corrections have been incorporated. Because they are in final form, no changes can be made after sending them. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the conventional way.

### **6.3 Author Services**

Online production tracking is available for your article through Author Services. Author Services enables authors to track their article - once it has been accepted - through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The authors will receive an e-mail with a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript.

### **6.4 Author Material Archive Policy**

Please note that if not specifically requested, publisher will dispose off hardcopy & electronic information submitted, after the two months of publication. If you require the return of any information submitted, please inform the Editorial Board or dean as soon as possible.

### **6.5 Offprint and Extra Copies**

A PDF offprint of the online-published article will be provided free of charge to the related author, and may be distributed according to the Publisher's terms and conditions. Additional paper offprint may be ordered by emailing us at: [editor@globaljournals.org](mailto:editor@globaljournals.org) .





Before start writing a good quality Computer Science Research Paper, let us first understand what is Computer Science Research Paper? So, Computer Science Research Paper is the paper which is written by professionals or scientists who are associated to Computer Science and Information Technology, or doing research study in these areas. If you are novel to this field then you can consult about this field from your supervisor or guide.

#### TECHNIQUES FOR WRITING A GOOD QUALITY RESEARCH PAPER:

**1. Choosing the topic:** In most cases, the topic is searched by the interest of author but it can be also suggested by the guides. You can have several topics and then you can judge that in which topic or subject you are finding yourself most comfortable. This can be done by asking several questions to yourself, like Will I be able to carry our search in this area? Will I find all necessary recourses to accomplish the search? Will I be able to find all information in this field area? If the answer of these types of questions will be "Yes" then you can choose that topic. In most of the cases, you may have to conduct the surveys and have to visit several places because this field is related to Computer Science and Information Technology. Also, you may have to do a lot of work to find all rise and falls regarding the various data of that subject. Sometimes, detailed information plays a vital role, instead of short information.

**2. Evaluators are human:** First thing to remember that evaluators are also human being. They are not only meant for rejecting a paper. They are here to evaluate your paper. So, present your Best.

**3. Think Like Evaluators:** If you are in a confusion or getting demotivated that your paper will be accepted by evaluators or not, then think and try to evaluate your paper like an Evaluator. Try to understand that what an evaluator wants in your research paper and automatically you will have your answer.

**4. Make blueprints of paper:** The outline is the plan or framework that will help you to arrange your thoughts. It will make your paper logical. But remember that all points of your outline must be related to the topic you have chosen.

**5. Ask your Guides:** If you are having any difficulty in your research, then do not hesitate to share your difficulty to your guide (if you have any). They will surely help you out and resolve your doubts. If you can't clarify what exactly you require for your work then ask the supervisor to help you with the alternative. He might also provide you the list of essential readings.

**6. Use of computer is recommended:** As you are doing research in the field of Computer Science, then this point is quite obvious.

**7. Use right software:** Always use good quality software packages. If you are not capable to judge good software then you can lose quality of your paper unknowingly. There are various software programs available to help you, which you can get through Internet.

**8. Use the Internet for help:** An excellent start for your paper can be by using the Google. It is an excellent search engine, where you can have your doubts resolved. You may also read some answers for the frequent question how to write my research paper or find model research paper. From the internet library you can download books. If you have all required books make important reading selecting and analyzing the specified information. Then put together research paper sketch out.

**9. Use and get big pictures:** Always use encyclopedias, Wikipedia to get pictures so that you can go into the depth.

**10. Bookmarks are useful:** When you read any book or magazine, you generally use bookmarks, right! It is a good habit, which helps to not to lose your continuity. You should always use bookmarks while searching on Internet also, which will make your search easier.

**11. Revise what you wrote:** When you write anything, always read it, summarize it and then finalize it.



**12. Make all efforts:** Make all efforts to mention what you are going to write in your paper. That means always have a good start. Try to mention everything in introduction, that what is the need of a particular research paper. Polish your work by good skill of writing and always give an evaluator, what he wants.

**13. Have backups:** When you are going to do any important thing like making research paper, you should always have backup copies of it either in your computer or in paper. This will help you to not to lose any of your important.

**14. Produce good diagrams of your own:** Always try to include good charts or diagrams in your paper to improve quality. Using several and unnecessary diagrams will degrade the quality of your paper by creating "hotchpotch." So always, try to make and include those diagrams, which are made by your own to improve readability and understandability of your paper.

**15. Use of direct quotes:** When you do research relevant to literature, history or current affairs then use of quotes become essential but if study is relevant to science then use of quotes is not preferable.

**16. Use proper verb tense:** Use proper verb tenses in your paper. Use past tense, to present those events that happened. Use present tense to indicate events that are going on. Use future tense to indicate future happening events. Use of improper and wrong tenses will confuse the evaluator. Avoid the sentences that are incomplete.

**17. Never use online paper:** If you are getting any paper on Internet, then never use it as your research paper because it might be possible that evaluator has already seen it or maybe it is outdated version.

**18. Pick a good study spot:** To do your research studies always try to pick a spot, which is quiet. Every spot is not for studies. Spot that suits you choose it and proceed further.

**19. Know what you know:** Always try to know, what you know by making objectives. Else, you will be confused and cannot achieve your target.

**20. Use good quality grammar:** Always use a good quality grammar and use words that will throw positive impact on evaluator. Use of good quality grammar does not mean to use tough words, that for each word the evaluator has to go through dictionary. Do not start sentence with a conjunction. Do not fragment sentences. Eliminate one-word sentences. Ignore passive voice. Do not ever use a big word when a diminutive one would suffice. Verbs have to be in agreement with their subjects. Prepositions are not expressions to finish sentences with. It is incorrect to ever divide an infinitive. Avoid clichés like the disease. Also, always shun irritating alliteration. Use language that is simple and straight forward. put together a neat summary.

**21. Arrangement of information:** Each section of the main body should start with an opening sentence and there should be a changeover at the end of the section. Give only valid and powerful arguments to your topic. You may also maintain your arguments with records.

**22. Never start in last minute:** Always start at right time and give enough time to research work. Leaving everything to the last minute will degrade your paper and spoil your work.

**23. Multitasking in research is not good:** Doing several things at the same time proves bad habit in case of research activity. Research is an area, where everything has a particular time slot. Divide your research work in parts and do particular part in particular time slot.

**24. Never copy others' work:** Never copy others' work and give it your name because if evaluator has seen it anywhere you will be in trouble.

**25. Take proper rest and food:** No matter how many hours you spend for your research activity, if you are not taking care of your health then all your efforts will be in vain. For a quality research, study is must, and this can be done by taking proper rest and food.

**26. Go for seminars:** Attend seminars if the topic is relevant to your research area. Utilize all your resources.



**27. Refresh your mind after intervals:** Try to give rest to your mind by listening to soft music or by sleeping in intervals. This will also improve your memory.

**28. Make colleagues:** Always try to make colleagues. No matter how sharper or intelligent you are, if you make colleagues you can have several ideas, which will be helpful for your research.

**29. Think technically:** Always think technically. If anything happens, then search its reasons, its benefits, and demerits.

**30. Think and then print:** When you will go to print your paper, notice that tables are not be split, headings are not detached from their descriptions, and page sequence is maintained.

**31. Adding unnecessary information:** Do not add unnecessary information, like, I have used MS Excel to draw graph. Do not add irrelevant and inappropriate material. These all will create superfluous. Foreign terminology and phrases are not apropos. One should NEVER take a broad view. Analogy in script is like feathers on a snake. Not at all use a large word when a very small one would be sufficient. Use words properly, regardless of how others use them. Remove quotations. Puns are for kids, not grunt readers. Amplification is a billion times of inferior quality than sarcasm.

**32. Never oversimplify everything:** To add material in your research paper, never go for oversimplification. This will definitely irritate the evaluator. Be more or less specific. Also too, by no means, ever use rhythmic redundancies. Contractions aren't essential and shouldn't be there used. Comparisons are as terrible as clichés. Give up ampersands and abbreviations, and so on. Remove commas, that are, not necessary. Parenthetical words however should be together with this in commas. Understatement is all the time the complete best way to put onward earth-shaking thoughts. Give a detailed literary review.

**33. Report concluded results:** Use concluded results. From raw data, filter the results and then conclude your studies based on measurements and observations taken. Significant figures and appropriate number of decimal places should be used. Parenthetical remarks are prohibitive. Proofread carefully at final stage. In the end give outline to your arguments. Spot out perspectives of further study of this subject. Justify your conclusion by at the bottom of them with sufficient justifications and examples.

**34. After conclusion:** Once you have concluded your research, the next most important step is to present your findings. Presentation is extremely important as it is the definite medium through which your research is going to be in print to the rest of the crowd. Care should be taken to categorize your thoughts well and present them in a logical and neat manner. A good quality research paper format is essential because it serves to highlight your research paper and bring to light all necessary aspects in your research.

## INFORMAL GUIDELINES OF RESEARCH PAPER WRITING

### Key points to remember:

- Submit all work in its final form.
- Write your paper in the form, which is presented in the guidelines using the template.
- Please note the criterion for grading the final paper by peer-reviewers.

### Final Points:

A purpose of organizing a research paper is to let people to interpret your effort selectively. The journal requires the following sections, submitted in the order listed, each section to start on a new page.

The introduction will be compiled from reference matter and will reflect the design processes or outline of basis that direct you to make study. As you will carry out the process of study, the method and process section will be constructed as like that. The result segment will show related statistics in nearly sequential order and will direct the reviewers next to the similar intellectual paths throughout the data that you took to carry out your study. The discussion section will provide understanding of the data and projections as to the implication of the results. The use of good quality references all through the paper will give the effort trustworthiness by representing an alertness of prior workings.



Writing a research paper is not an easy job no matter how trouble-free the actual research or concept. Practice, excellent preparation, and controlled record keeping are the only means to make straightforward the progression.

**General style:**

Specific editorial column necessities for compliance of a manuscript will always take over from directions in these general guidelines.

To make a paper clear

- Adhere to recommended page limits

Mistakes to evade

- Insertion a title at the foot of a page with the subsequent text on the next page
- Separating a table/chart or figure - impound each figure/table to a single page
- Submitting a manuscript with pages out of sequence

In every sections of your document

- Use standard writing style including articles ("a", "the," etc.)
- Keep on paying attention on the research topic of the paper
- Use paragraphs to split each significant point (excluding for the abstract)
- Align the primary line of each section
- Present your points in sound order
- Use present tense to report well accepted
- Use past tense to describe specific results
- Shun familiar wording, don't address the reviewer directly, and don't use slang, slang language, or superlatives
- Shun use of extra pictures - include only those figures essential to presenting results

**Title Page:**

Choose a revealing title. It should be short. It should not have non-standard acronyms or abbreviations. It should not exceed two printed lines. It should include the name(s) and address (es) of all authors.



## Abstract:

The summary should be two hundred words or less. It should briefly and clearly explain the key findings reported in the manuscript-- must have precise statistics. It should not have abnormal acronyms or abbreviations. It should be logical in itself. Shun citing references at this point.

An abstract is a brief distinct paragraph summary of finished work or work in development. In a minute or less a reviewer can be taught the foundation behind the study, common approach to the problem, relevant results, and significant conclusions or new questions.

Write your summary when your paper is completed because how can you write the summary of anything which is not yet written? Wealth of terminology is very essential in abstract. Yet, use comprehensive sentences and do not let go readability for brevity. You can maintain it succinct by phrasing sentences so that they provide more than lone rationale. The author can at this moment go straight to shortening the outcome. Sum up the study, with the subsequent elements in any summary. Try to maintain the initial two items to no more than one ruling each.

- Reason of the study - theory, overall issue, purpose
- Fundamental goal
- To the point depiction of the research
- Consequences, including definite statistics - if the consequences are quantitative in nature, account quantitative data; results of any numerical analysis should be reported
- Significant conclusions or questions that track from the research(es)

## Approach:

- Single section, and succinct
- As an outline of job done, it is always written in past tense
- A conceptual should situate on its own, and not submit to any other part of the paper such as a form or table
- Center on shortening results - bound background information to a verdict or two, if completely necessary
- What you account in an abstract must be regular with what you reported in the manuscript
- Exact spelling, clearness of sentences and phrases, and appropriate reporting of quantities (proper units, important statistics) are just as significant in an abstract as they are anywhere else

## Introduction:

The **Introduction** should "introduce" the manuscript. The reviewer should be presented with sufficient background information to be capable to comprehend and calculate the purpose of your study without having to submit to other works. The basis for the study should be offered. Give most important references but shun difficult to make a comprehensive appraisal of the topic. In the introduction, describe the problem visibly. If the problem is not acknowledged in a logical, reasonable way, the reviewer will have no attention in your result. Speak in common terms about techniques used to explain the problem, if needed, but do not present any particulars about the protocols here. Following approach can create a valuable beginning:

- Explain the value (significance) of the study
- Shield the model - why did you employ this particular system or method? What is its compensation? You strength remark on its appropriateness from a abstract point of vision as well as point out sensible reasons for using it.
- Present a justification. Status your particular theory (es) or aim(s), and describe the logic that led you to choose them.
- Very for a short time explain the tentative propose and how it skilled the declared objectives.

## Approach:

- Use past tense except for when referring to recognized facts. After all, the manuscript will be submitted after the entire job is done.
- Sort out your thoughts; manufacture one key point with every section. If you make the four points listed above, you will need a least of four paragraphs.



- Present surroundings information only as desirable in order hold up a situation. The reviewer does not desire to read the whole thing you know about a topic.
- Shape the theory/purpose specifically - do not take a broad view.
- As always, give awareness to spelling, simplicity and correctness of sentences and phrases.

#### **Procedures (Methods and Materials):**

This part is supposed to be the easiest to carve if you have good skills. A sound written Procedures segment allows a capable scientist to replacement your results. Present precise information about your supplies. The suppliers and clarity of reagents can be helpful bits of information. Present methods in sequential order but linked methodologies can be grouped as a segment. Be concise when relating the protocols. Attempt for the least amount of information that would permit another capable scientist to spare your outcome but be cautious that vital information is integrated. The use of subheadings is suggested and ought to be synchronized with the results section. When a technique is used that has been well described in another object, mention the specific item describing a way but draw the basic principle while stating the situation. The purpose is to text all particular resources and broad procedures, so that another person may use some or all of the methods in one more study or referee the scientific value of your work. It is not to be a step by step report of the whole thing you did, nor is a methods section a set of orders.

#### **Materials:**

- Explain materials individually only if the study is so complex that it saves liberty this way.
- Embrace particular materials, and any tools or provisions that are not frequently found in laboratories.
- Do not take in frequently found.
- If use of a definite type of tools.
- Materials may be reported in a part section or else they may be recognized along with your measures.

#### **Methods:**

- Report the method (not particulars of each process that engaged the same methodology)
- Describe the method entirely
- To be succinct, present methods under headings dedicated to specific dealings or groups of measures
- Simplify - details how procedures were completed not how they were exclusively performed on a particular day.
- If well known procedures were used, account the procedure by name, possibly with reference, and that's all.

#### **Approach:**

- It is embarrassed or not possible to use vigorous voice when documenting methods with no using first person, which would focus the reviewer's interest on the researcher rather than the job. As a result when script up the methods most authors use third person passive voice.
- Use standard style in this and in every other part of the paper - avoid familiar lists, and use full sentences.

#### **What to keep away from**

- Resources and methods are not a set of information.
- Skip all descriptive information and surroundings - save it for the argument.
- Leave out information that is immaterial to a third party.

#### **Results:**

The principle of a results segment is to present and demonstrate your conclusion. Create this part a entirely objective details of the outcome, and save all understanding for the discussion.

The page length of this segment is set by the sum and types of data to be reported. Carry on to be to the point, by means of statistics and tables, if suitable, to present consequences most efficiently. You must obviously differentiate material that would usually be incorporated in a study editorial from any unprocessed data or additional appendix matter that would not be available. In fact, such matter should not be submitted at all except requested by the instructor.



## Content

- Sum up your conclusion in text and demonstrate them, if suitable, with figures and tables.
- In manuscript, explain each of your consequences, point the reader to remarks that are most appropriate.
- Present a background, such as by describing the question that was addressed by creation an exacting study.
- Explain results of control experiments and comprise remarks that are not accessible in a prescribed figure or table, if appropriate.
- Examine your data, then prepare the analyzed (transformed) data in the form of a figure (graph), table, or in manuscript form.

### What to stay away from

- Do not discuss or infer your outcome, report surroundings information, or try to explain anything.
- Not at all, take in raw data or intermediate calculations in a research manuscript.
- Do not present the similar data more than once.
- Manuscript should complement any figures or tables, not duplicate the identical information.
- Never confuse figures with tables - there is a difference.

### Approach

- As forever, use past tense when you submit to your results, and put the whole thing in a reasonable order.
- Put figures and tables, appropriately numbered, in order at the end of the report
- If you desire, you may place your figures and tables properly within the text of your results part.

### Figures and tables

- If you put figures and tables at the end of the details, make certain that they are visibly distinguished from any attach appendix materials, such as raw facts
- Despite of position, each figure must be numbered one after the other and complete with subtitle
- In spite of position, each table must be titled, numbered one after the other and complete with heading
- All figure and table must be adequately complete that it could situate on its own, divide from text

### Discussion:

The Discussion is expected the trickiest segment to write and describe. A lot of papers submitted for journal are discarded based on problems with the Discussion. There is no head of state for how long a argument should be. Position your understanding of the outcome visibly to lead the reviewer through your conclusions, and then finish the paper with a summing up of the implication of the study. The purpose here is to offer an understanding of your results and hold up for all of your conclusions, using facts from your research and generally accepted information, if suitable. The implication of result should be visibly described. Infer your data in the conversation in suitable depth. This means that when you clarify an observable fact you must explain mechanisms that may account for the observation. If your results vary from your prospect, make clear why that may have happened. If your results agree, then explain the theory that the proof supported. It is never suitable to just state that the data approved with prospect, and let it drop at that.

- Make a decision if each premise is supported, discarded, or if you cannot make a conclusion with assurance. Do not just dismiss a study or part of a study as "uncertain."
- Research papers are not acknowledged if the work is imperfect. Draw what conclusions you can based upon the results that you have, and take care of the study as a finished work
- You may propose future guidelines, such as how the experiment might be personalized to accomplish a new idea.
- Give details all of your remarks as much as possible, focus on mechanisms.
- Make a decision if the tentative design sufficiently addressed the theory, and whether or not it was correctly restricted.
- Try to present substitute explanations if sensible alternatives be present.
- One research will not counter an overall question, so maintain the large picture in mind, where do you go next? The best studies unlock new avenues of study. What questions remain?
- Recommendations for detailed papers will offer supplementary suggestions.

### Approach:

- When you refer to information, differentiate data generated by your own studies from available information
- Submit to work done by specific persons (including you) in past tense.
- Submit to generally acknowledged facts and main beliefs in present tense.



## THE ADMINISTRATION RULES

Please carefully note down following rules and regulation before submitting your Research Paper to Global Journals Inc. (US):

**Segment Draft and Final Research Paper:** You have to strictly follow the template of research paper. If it is not done your paper may get rejected.

- The **major constraint** is that you must independently make all content, tables, graphs, and facts that are offered in the paper. You must write each part of the paper wholly on your own. The Peer-reviewers need to identify your own perceptives of the concepts in your own terms. NEVER extract straight from any foundation, and never rephrase someone else's analysis.
- Do not give permission to anyone else to "PROOFREAD" your manuscript.
- **Methods to avoid Plagiarism is applied by us on every paper, if found guilty, you will be blacklisted by all of our collaborated research groups, your institution will be informed for this and strict legal actions will be taken immediately.)**
- To guard yourself and others from possible illegal use please do not permit anyone right to use to your paper and files.





CRITERION FOR GRADING A RESEARCH PAPER (COMPILATION)  
BY GLOBAL JOURNALS INC. (US)

Please note that following table is only a Grading of "Paper Compilation" and not on "Performed/Stated Research" whose grading solely depends on Individual Assigned Peer Reviewer and Editorial Board Member. These can be available only on request and after decision of Paper. This report will be the property of Global Journals Inc. (US).

Topics	Grades		
	A-B	C-D	E-F
<i>Abstract</i>	Clear and concise with appropriate content, Correct format. 200 words or below	Unclear summary and no specific data, Incorrect form  Above 200 words	No specific data with ambiguous information  Above 250 words
<i>Introduction</i>	Containing all background details with clear goal and appropriate details, flow specification, no grammar and spelling mistake, well organized sentence and paragraph, reference cited	Unclear and confusing data, appropriate format, grammar and spelling errors with unorganized matter	Out of place depth and content, hazy format
<i>Methods and Procedures</i>	Clear and to the point with well arranged paragraph, precision and accuracy of facts and figures, well organized subheads	Difficult to comprehend with embarrassed text, too much explanation but completed	Incorrect and unorganized structure with hazy meaning
<i>Result</i>	Well organized, Clear and specific, Correct units with precision, correct data, well structuring of paragraph, no grammar and spelling mistake	Complete and embarrassed text, difficult to comprehend	Irregular format with wrong facts and figures
<i>Discussion</i>	Well organized, meaningful specification, sound conclusion, logical and concise explanation, highly structured paragraph reference cited	Wordy, unclear conclusion, spurious	Conclusion is not cited, unorganized, difficult to comprehend
<i>References</i>	Complete and correct format, well organized	Beside the point, Incomplete	Wrong format and structuring



# INDEX

---

---

## **A**

Abudayyak · 6, 7, 8, 9  
Angiogenic · 23

---

## **B**

Bioimpedance · 1, 4  
Bisphenol · 21, 22, 24

---

## **D**

Dibenzofurans · 22  
Dyspnea · 1, 2, 3, 4

---

## **E**

Estrogensignaling · 23

---

## **G**

Glomerulonephritis · 3  
Glucocorticoids · 16

---

## **H**

Hemodialysis · 1, 4, 5  
Hypervolemia · 1, 2, 3

---

## **K**

Keratinocytes · 8, 9  
Kestenbaum · 3, 5

---

## **M**

Mallamaci · 3, 4  
Malondialdehyde · 6

---

## **N**

Nephelometry · 15  
Neuronal · 6  
Normotensives · 15, 16, 17

---

## **P**

Parasternal · 2  
Perreault · 6, 8, 10  
Plasminogen · 17, 18  
Pollack · 31  
Polyhalogenated · 21, 22  
Prehypertensives · 17  
Proinflammatory · 15

---

## **R**

Ribosylation · 22

---

## **S**

Steroidogenesis · 22  
Sumoylation · 22

---

## **T**

Teratogenesis · 23  
Trichomonas · 31

---

## **U**

Ultrafiltration · 1, 2, 4

---

## **X**

Xenobiotics · 23



save our planet



# Global Journal of Medical Research

---

Visit us on the Web at [www.GlobalJournals.org](http://www.GlobalJournals.org) | [www.MedicalResearchJournal.org](http://www.MedicalResearchJournal.org)  
or email us at [helpdesk@globaljournals.org](mailto:helpdesk@globaljournals.org)

ISSN 9755896



© Global Journals